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Abstract	  
	  Modern	  medicine	  has	  a	  continued	  reliance	  on	  allogeneic	  blood	  products.	  This	  is	  an	  expensive,	  scarce	  resource	  with	  inherent	  risks	  to	  patients.	  There	  is	  no	  current	  literature	  evaluating	  the	  level	  of	  knowledge	  and	  awareness	  of	  rational	  blood	  product	  use	  in	  South	  Africa.	  	  The	  purpose	  of	  this	  research	  was	  to	  describe	  the	  level	  of	  clinicians’	  knowledge	  and	  awareness	  related	  to	  the	  ordering	  and	  administration	  of	  blood	  products	  from	  the	  South	  African	  National	  Blood	  Service	  for	  perioperative	  patients	  at	  Chris	  Hani	  Baragwanath	  Academic	  Hospital.	  	  A	  prospective,	  descriptive,	  contextual	  study	  design	  was	  used.	  A	  questionnaire	  and	  an	  information	  letter	  were	  distributed.	  	  A	  total	  of	  172	  of	  210	  (81.9%)	  distributed	  questionnaires	  were	  returned.	  Departments	  included	  were	  Anaesthesiology,	  General	  Surgery	  and	  Trauma,	  Orthopaedic	  Surgery	  and	  Obstetrics	  and	  Gynaecology.	  Interns,	  medical	  officers,	  registrars	  and	  consultants	  were	  included.	  	  Clinicians’	  knowledge	  of	  the	  risks	  associated	  with	  blood	  product	  administration	  appears	  to	  be	  poor.	  Awareness	  of	  consent,	  costs,	  ordering	  and	  administration	  protocols	  was	  also	  disappointing.	  In	  this	  study	  respondents	  from	  Anaesthesiology	  performed	  significantly	  better	  than	  their	  colleagues	  and	  consultants	  performed	  significantly	  better	  than	  their	  junior	  colleagues.	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Chapter	  1	  -­‐	  Overview	  of	  the	  study	  
	  In	  this	  chapter	  the	  background	  of	  this	  research	  is	  introduced	  followed	  by	  the	  purpose	  and	  objectives.	  The	  research	  assumptions,	  demarcation	  of	  the	  study	  field,	  ethical	  considerations,	  research	  methodology,	  significance	  of	  the	  study,	  validity,	  reliability	  and	  study	  limitations	  follow.	  
1.1	  Background	  	  Modern	  medicine	  has	  a	  continued	  reliance	  on	  allogeneic	  blood	  products.	  This	  is	  an	  expensive	  and	  scarce	  resource,	  with	  inherent	  risks	  to	  patients.	  Escalating	  costs	  and	  declining	  supplies	  have	  deepened	  the	  need	  to	  rationalise	  transfusion	  practice.	  	  The	  Transfusion	  Requirements	  In	  Critical	  Care	  (TRICC)	  study	  (1)	  in	  1999	  directed	  subsequent	  recommendations	  and	  guidelines	  for	  the	  use	  of	  red	  cell	  concentrate	  (RCC).	  A	  liberal	  approach	  to	  transfusion	  was	  compared	  to	  a	  restrictive	  approach	  in	  critically	  ill	  patients.	  It	  was	  found	  that	  the	  restrictive	  approach	  was	  as	  effective	  and	  possibly	  superior	  to	  a	  liberal	  approach	  (1).	  This	  recommendation	  has	  been	  extended	  to	  most	  patient	  groups	  in	  a	  2012	  Cochrane	  Collaboration	  Review	  on	  transfusion	  thresholds	  (2).	  	  	  The	  rational	  use	  of	  transfused	  platelets	  and	  fresh	  frozen	  plasma	  (FFP)	  is	  less	  well	  defined.	  A	  Cochrane	  Collaboration	  Review	  (3)	  on	  prophylactic	  platelet	  transfusion	  found	  no	  evidence	  that	  a	  prophylactic	  platelet	  transfusion	  policy	  prevents	  bleeding	  and	  that	  a	  platelet	  count	  of	  10	  x	  109/litre	  should	  remain	  the	  recommended	  level	  for	  triggering	  a	  transfusion	  to	  prevent	  spontaneous	  bleeding.	  	  	  FFP	  appears	  to	  have	  the	  highest	  rate	  of	  inappropriate	  use	  compared	  with	  other	  blood	  products	  (4,	  5).	  Significant	  variation	  in	  usage	  is	  also	  seen	  (6,	  7).	  FFP	  has	  not	  been	  proven	  to	  be	  of	  benefit	  in	  the	  setting	  of	  abnormal	  laboratory	  coagulation	  tests	  (4,	  5,	  8),	  although	  prophylactic	  transfusion	  may	  account	  for	  up	  to	  50%	  of	  use	  (6,	  7,	  9,	  10).	  Generally,	  FFP	  administration	  is	  not	  rational	  and	  is	  not	  given	  in	  sufficient	  amounts	  (9).	  Visser	  et	  al	  (11)	  published	  an	  evaluation	  of	  FFP	  use	  in	  2012	  in	  a	  South	  African	  tertiary	  hospital.	  Transfusions	  were	  considered	  inappropriate	  in	  39,5%	  of	  cases.	  The	  authors	  cited	  lack	  of	  knowledge	  regarding	  indications	  for	  FFP	  administration	  and	  stated	  that	  intervention	  is	  necessary	  to	  improve	  rational	  use.	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Most	  authors	  and	  clinicians	  note	  a	  clinical	  assessment	  is	  fundamentally	  important	  in	  the	  decision	  to	  transfuse	  blood	  products	  (12-­‐15).	  Many	  of	  the	  guidelines	  do	  encourage	  this	  practice	  but	  specific	  awareness	  of	  the	  guidelines	  seems	  to	  be	  lacking	  as	  demonstrated	  by	  specific	  questions	  asked	  in	  a	  number	  of	  surveys	  (10,	  12-­‐15).	  	  Despite	  considerable	  interest	  in	  blood	  product	  alternatives,	  these	  products	  have	  limited	  application	  in	  very	  specific	  circumstances	  (16-­‐18).	  A	  complete	  alternative	  to	  any	  blood	  product	  has	  not	  been	  convincingly	  proven.	  	  In	  2011,	  43	  657	  procedures	  were	  performed	  in	  all	  operating	  theatres	  at	  Chris	  Hani	  Baragwanath	  Academic	  Hospital	  (CHBAH)	  (19).	  Between	  5000	  and	  6000	  blood	  products	  are	  ordered	  monthly	  from	  the	  South	  African	  National	  Blood	  Service	  (SANBS)	  at	  CHBAH	  (20).	  Up	  to	  30%	  of	  these	  orders	  are	  cancelled	  or	  wasted	  (20).	  This	  includes	  returned	  units	  that	  must	  be	  discarded	  and	  units	  that	  are	  not	  collected	  from	  the	  SANBS	  after	  being	  ordered.	  	  	  In	  the	  South	  African	  setting	  it	  is	  of	  paramount	  importance	  that	  medical	  professionals	  have	  the	  competencies,	  skills	  and	  knowledge	  to	  administer	  the	  limited	  and	  expensive	  blood	  products	  safely	  to	  the	  most	  appropriate	  patients.	  There	  is	  no	  current	  literature	  evaluating	  the	  level	  of	  knowledge	  and	  awareness	  of	  rational	  blood	  product	  use	  in	  this	  country.	  	  
1.2	  Problem	  statement	  
	  CHBAH	  utilises	  the	  services	  of	  the	  SANBS	  to	  provide	  allogeneic	  blood	  products	  for	  use	  on	  patients	  in	  the	  form	  of	  blood	  components.	  Blood	  product	  supply	  is	  in	  high	  demand	  and	  is	  expensive.	  Medical	  doctors	  are	  responsible	  for	  the	  ordering	  and	  prescription	  to	  administer	  blood	  component	  therapy	  at	  CHBAH.	  	  The	  perceived	  situation	  of	  current	  practice	  is	  that	  medical	  personnel	  lack	  the	  competencies,	  skills	  and	  knowledge	  related	  to	  risks,	  cost,	  appropriate	  ordering,	  administration,	  guidelines	  and	  physiology	  of	  blood	  product	  transfusion.	  The	  consequence	  of	  this	  is	  blood	  product	  use	  and	  costs	  are	  not	  optimal	  as	  revealed	  by	  an	  audit	  of	  these	  services	  at	  CHBAH	  (21).	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1.3	  Purpose	  
	  The	  purpose	  of	  this	  research	  was	  to	  describe	  the	  level	  of	  clinicians’	  knowledge	  and	  awareness	  related	  to	  all	  aspects	  of	  the	  ordering	  and	  administration	  of	  blood	  products	  from	  the	  SANBS	  for	  perioperative	  patients	  at	  CHBAH.	  	  
1.4	  Objectives	  
	  The	  primary	  objectives	  of	  this	  study	  were	  to	  determine	  the	  knowledge	  and	  awareness	  of	  clinicians	  with	  regard	  to:	  
• Risks	  associated	  with	  the	  transfusion	  of	  blood	  products.	  
• Resources	  and	  costs	  associated	  with	  the	  transfusion	  of	  blood	  products.	  
• Donations,	  ordering	  and	  return	  of	  blood	  products.	  
• Safe	  administration	  of	  blood	  products	  to	  a	  patient.	  
• Transfusion	  thresholds	  and	  triggers	  for	  blood	  product	  administration.	  	  The	  secondary	  objectives	  of	  this	  study	  were	  to	  compare	  knowledge	  levels	  among	  the	  different	  specialty	  departments	  and	  clinician	  ranks.	  	  
1.5	  Research	  assumptions	  
	  The	  following	  definitions	  were	  used:	  
	  
South	  African	  National	  Blood	  Service	  (SANBS):	  	  a	  non-­‐profit	  organisation	  that	  provides	  patients	  with	  sufficient,	  safe	  quality	  blood	  products	  and	  medical	  services	  related	  to	  blood	  transfusion	  in	  an	  equitable	  and	  cost-­‐effective	  manner	  (22,	  23).	  
	  
Blood	  product:	  a	  component	  of	  blood	  collected	  from	  a	  human	  donor	  (23).	  For	  purposes	  of	  this	  study	  this	  was	  confined	  to	  RCC,	  platelets	  and	  FFP.	  	  
Crossmatch:	  units	  of	  RCC	  are	  tested	  for	  compatibility	  with	  a	  specific	  specimen	  for	  transfusion	  (23-­‐25).	  Standard	  crossmatch	  is	  done	  within	  two	  hours	  by	  the	  SANBS.	  An	  emergency	  crossmatch,	  completed	  in	  30	  minutes,	  only	  confirms	  partial	  compatibility	  (23-­‐25).	  Crossmatched	  products	  will	  be	  held	  in	  reserve	  for	  24	  hours	  unless	  otherwise	  indicated	  by	  the	  attending	  doctor.	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Type	  and	  screen:	  a	  patient’s	  blood	  specimen	  that	  is	  tested	  to	  determine	  blood	  group	  and	  ensure	  that	  it	  does	  not	  contain	  problematic	  antibodies	  which	  could	  delay	  finding	  compatible	  blood	  (23,	  24).	  The	  specimen	  is	  held	  for	  96	  hours	  at	  the	  SANBS.	  	  
Red	  cell	  concentrate	  (RCC):	  	  erythrocytes	  obtained	  from	  a	  unit	  of	  whole	  blood	  that	  have	  the	  plasma	  and	  buffy	  coat	  removed	  (23,	  24).	  	  
Platelets:	  platelets	  for	  transfusion	  are	  prepared	  from	  the	  buffy	  layers	  of	  whole	  blood	  donations	  within	  8	  hours	  of	  collection	  and	  stored	  with	  continuous	  agitation	  for	  up	  to	  5	  days	  at	  22	  °C	  (23).	  	  
Fresh	  frozen	  plasma	  (FFP):	  plasma	  that	  is	  separated	  from	  anticoagulated	  whole	  blood	  and	  is	  frozen	  within	  18	  hours	  of	  donation	  (23).	  FFP	  contains	  all	  coagulation	  factors	  at	  physiological	  levels	  (25).	  	  
Major	  surgical	  blood	  ordering	  schedule	  (MSBOS):	  consists	  of	  a	  list	  of	  the	  recommended	  maximum	  number	  of	  units	  of	  blood	  which	  are	  routinely	  crossmatched	  for	  elective	  procedures	  (26).	  	  
Health	  Professions	  Council	  of	  South	  Africa	  (HPCSA):	  	  the	  statutory	  body	  which	  governs	  the	  professional	  accreditation	  of	  doctors	  and	  other	  health	  professionals	  in	  South	  Africa	  (27).	  Categories	  of	  doctors	  that	  are	  defined	  by	  the	  HPCSA	  and	  were	  used	  in	  this	  study	  are	  described	  below.	  	  	  
Intern:	  A	  doctor	  who	  has	  graduated	  from	  university	  and	  is	  completing	  further	  supervised	  training	  for	  a	  period	  of	  two	  years	  as	  recognised	  by	  the	  HPCSA	  (28).	  This	  category	  of	  doctors	  is	  not	  registered	  by	  the	  HPCSA	  for	  independent	  practice.	  	  
Community	  service	  doctor:	  a	  doctor	  who	  is	  completing	  his/her	  community	  service	  as	  prescribed	  by	  the	  HPCSA	  prior	  to	  being	  granted	  full	  registration	  for	  independent	  practice	  (28,	  29).	  This	  doctor	  has	  usually	  completed	  two	  years	  internship	  that	  is	  acknowledged	  by	  the	  HPCSA	  as	  an	  extended	  period	  of	  training	  following	  graduation	  with	  a	  medical	  degree.	  For	  the	  purposes	  of	  this	  study	  these	  doctors	  are	  included	  in	  the	  medical	  officer	  group.	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Medical	  officer:	  a	  doctor	  employed	  by	  the	  provincial	  government	  in	  a	  designated	  medical	  officer	  post	  (29).	  These	  doctors	  may	  have	  no	  formal	  postgraduate	  training	  in	  the	  discipline	  in	  which	  they	  may	  work.	  These	  doctors	  are	  registered	  by	  the	  HPCSA	  for	  independent	  practice.	  	  
Registrar:	  a	  doctor	  who	  is	  in	  the	  process	  of	  acquiring	  a	  specialist	  qualification	  endorsed	  by	  the	  HPCSA	  (30).	  	  
Consultant:	  a	  doctor	  who	  has	  a	  specialist	  qualification	  endorsed	  by	  the	  HPCSA	  (31).	  	  
Clinician:	  for	  the	  purposes	  of	  this	  research	  all	  the	  groups	  of	  doctors	  described	  above	  were	  referred	  to	  as	  clinicians.	  	  
Formal	  blood	  product	  education:	  for	  the	  purposes	  of	  this	  research	  this	  comprises	  of	  the	  annual	  SANBS	  seminar	  at	  CHBAH,	  annual	  intern	  cardiopulmonary	  resuscitation	  course	  at	  CHBAH	  and	  departmental	  academic	  meetings.	  	  
1.6	  Demarcation	  of	  the	  study	  field	  	  The	  study	  was	  conducted	  at	  CHBAH.	  This	  hospital	  is	  a	  large	  central	  hospital	  occupying	  0.70	  km²	  with	  3	  200	  beds	  and	  6	  760	  staff	  members	  (32).	  It	  is	  located	  in	  the	  Soweto	  area	  of	  Johannesburg	  and	  it	  is	  one	  of	  the	  teaching	  hospitals	  affiliated	  to	  the	  University	  of	  the	  Witwatersrand	  (32).	  	  	  
1.7	  Ethical	  considerations	  
	  Verbal	  assent	  was	  obtained	  from	  the	  Heads	  of	  Departments	  of	  Anaesthesiology,	  General	  Surgery	  and	  Trauma,	  Orthopaedic	  Surgery,	  Obstetrics	  and	  Gynaecology	  and	  the	  Chairman	  of	  the	  CHBAH	  Local	  Blood	  Committee	  prior	  to	  the	  proposal	  being	  submitted	  for	  formal	  approval.	  	  Ethics	  approval	  was	  obtained	  from	  the	  Human	  Research	  Ethics	  Committee	  (Medical)	  (Appendix	  1)	  and	  the	  Post-­‐Graduate	  Committee	  of	  the	  University	  of	  the	  Witwatersrand	  (Appendix	  2).	  Subsequently,	  consent	  to	  perform	  the	  study	  was	  obtained	  from	  the	  Medical	  Advisory	  Committee	  of	  CHBAH	  (Appendix	  3).	  	  Clinicians	  were	  invited	  to	  take	  part	  in	  the	  study	  and	  were	  given	  a	  self-­‐administered	  questionnaire	  (Appendix	  4).	  The	  questionnaire	  contained	  an	  information	  letter	  (Appendix	  5)	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detailing	  the	  purpose	  of	  the	  study,	  ethics	  and	  CHBAH	  Medical	  Advisory	  Committee	  approval.	  The	  agreement	  to	  complete	  the	  questionnaire	  implied	  consent.	  Anonymity	  of	  participants	  and	  questionnaires	  was	  ensured	  by	  not	  recording	  participants’	  names	  on	  the	  questionnaires,	  which	  were	  then	  placed	  in	  a	  sealed	  envelope	  in	  a	  container	  with	  other	  questionnaires.	  Furthermore,	  confidentiality	  was	  ensured	  as	  the	  researcher	  and	  supervisors	  were	  the	  only	  people	  to	  have	  access	  to	  the	  raw	  data.	  	  	  The	  study	  was	  conducted	  in	  adherence	  to	  the	  principles	  of	  the	  Declaration	  of	  Helsinki	  2008	  (33)	  and	  South	  African	  Good	  Clinical	  Practice	  Guidelines	  (34).	  	  
1.8	  Research	  methodology	  
	  
1.8.1	  Research	  design	  	  A	  prospective,	  descriptive,	  contextual	  study	  design	  was	  used.	  	  	  
1.8.2	  Study	  population	  
	  Clinicians	  working	  with	  perioperative	  patients	  in	  the	  Anaesthesiology,	  General	  Surgery	  and	  Trauma,	  Orthopaedic	  Surgery	  and	  Obstetrics	  and	  Gynaecology	  Departments	  belonging	  to	  the	  professional	  ranks	  of	  intern,	  medical	  officer,	  registrar	  and	  consultant	  formed	  the	  population	  group	  studied.	  	  
1.8.3	  Study	  sample	  
	  
Sample	  size	  
	  Approximately	  600	  doctors	  are	  employed	  at	  CHBAH	  (32),	  of	  which	  about	  200	  work	  with	  perioperative	  patients	  (32).	  The	  sample	  size	  was	  realised	  by	  the	  number	  of	  respondents	  who	  completed	  the	  questionnaire.	  
	  
Sampling	  method	  
	  A	  convenience	  sampling	  method,	  which	  involves	  the	  selection	  of	  readily	  available	  subjects	  or	  objects	  for	  a	  study	  (35),	  was	  used.	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Inclusion	  criteria	  
	  Clinicians	  from	  the	  Departments	  of	  Anaesthesiology,	  General	  Surgery	  and	  Trauma,	  Orthopaedic	  Surgery	  and	  Obstetrics	  and	  Gynaecology.	  	  
Exclusion	  criteria	  
• Clinicians	  who	  indicate	  that	  they	  had	  never	  been	  involved	  in	  the	  administration	  of	  blood	  products	  at	  CHBAH.	  
• Clinicians	  who	  declined	  to	  participate.	  
• Clinicians	  on	  annual,	  special	  or	  sick	  leave	  at	  the	  time	  of	  data	  collection.	  
1.8.4	  Self-­‐administered	  questionnaire	  	  
	  
Questionnaire	  development	  
	  In	  order	  to	  develop	  a	  questionnaire	  that	  would	  accurately	  assess	  competencies,	  skills	  and	  knowledge	  related	  to	  blood	  products	  amongst	  clinicians	  the	  literature	  was	  reviewed.	  	  	  Questions	  were	  formulated	  using	  previous	  surveys	  and	  textbooks	  (10,	  12-­‐15,	  26,	  36-­‐38)	  and	  adapted	  using	  the	  SANBS	  Clinical	  Guidelines	  for	  the	  use	  of	  Blood	  Products	  in	  South	  Africa	  (23).	  	  Three	  senior	  anaesthesiologists	  and	  a	  senior	  haematologist,	  all	  with	  blood	  product	  expertise,	  validated	  the	  questionnaire.	  This	  was	  done	  in	  order	  to	  ensure	  validity	  and	  reliability.	  	  
Questionnaire	  distribution	  	  All	  clinicians	  fitting	  the	  inclusion	  criteria	  within	  the	  departments	  outlined	  were	  identified.	  The	  questionnaires	  and	  an	  information	  letter	  were	  distributed	  at	  academic	  meetings	  to	  those	  clinicians	  who	  agreed	  to	  participate	  in	  the	  study.	  	  
	  
1.8.5	  Data	  analysis	  
	  Data	  were	  analysed	  using	  descriptive	  and	  inferential	  statistics	  using	  Microsoft	  Excel	  for	  Mac	  2011	  and	  GraphPad	  InStat.	  For	  descriptive	  analysis	  of	  data	  that	  were	  normally	  distributed	  mean	  and	  standard	  deviation	  (SD)	  were	  used.	  Analysis	  of	  variance	  testing	  (ANOVA)	  testing	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was	  used	  to	  compare	  means	  between	  groups.	  A	  p-­‐value	  <	  0.05	  was	  taken	  as	  statistically	  significant.	  	  
1.9	  Significance	  of	  the	  study	  	  This	  study	  was	  designed	  to	  evaluate	  blood	  product	  competencies,	  skills	  and	  knowledge	  of	  clinicians	  at	  CHBAH	  and	  may	  provide	  a	  baseline	  understanding	  of	  practice	  surrounding	  administration.	  Furthermore,	  it	  may	  lay	  a	  foundation	  for	  further	  studies	  to	  be	  conducted	  on	  this	  topic.	  	  This	  research	  may	  be	  of	  value	  to	  CHBAH	  management,	  the	  CHBAH	  Local	  Blood	  Committee	  and	  the	  SANBS	  as	  the	  results	  may	  be	  used	  to	  optimise	  utilisation	  of	  blood	  products.	  These	  resources	  are	  under	  constant	  pressure	  and	  rationalisation	  of	  ordering	  and	  administration	  may	  be	  of	  benefit.	  	  
1.10	  Validity	  and	  reliability	  
	  In	  this	  study	  the	  questionnaire	  was	  assessed	  and	  validated	  by	  three	  senior	  anaesthesiologists	  and	  a	  senior	  haematologist,	  all	  with	  blood	  product	  expertise.	  It	  was	  developed	  following	  an	  extensive	  literature	  review.	  Instruments	  used	  in	  similar	  studies	  were	  used	  as	  a	  comparison	  for	  the	  development	  of	  the	  questionnaire.	  This	  ensured	  validity	  and	  reliability	  of	  the	  research	  tool.	  	  
1.11	  Project	  outline	  	  Chapter	  1:	  Overview	  of	  the	  study	  Chapter	  2:	  Literature	  review	  and	  background	  Chapter	  3:	  Research	  design	  and	  methods	  Chapter	  4:	  Data	  analysis	  and	  discussion	  of	  results	  Chapter	  5:	  Summary,	  limitations,	  recommendations	  and	  conclusions	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1.12	  Conclusion	  
	  In	  this	  chapter	  the	  background	  of	  this	  research	  was	  introduced	  followed	  by	  the	  purpose	  and	  objectives.	  The	  research	  assumptions,	  demarcation	  of	  the	  study	  field,	  ethical	  considerations,	  research	  methodology,	  significance	  of	  the	  study,	  validity	  and	  reliability	  followed.	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Chapter	  2	  -­‐	  Literature	  review	  and	  background	  
	  
2.1	  Introduction	  
	  The	  WHO	  launched	  a	  patient	  safety	  programme	  in	  2008	  with	  the	  slogan	  of	  “better	  knowledge	  for	  safer	  care”	  (39).	  This	  programme	  urges	  the	  prioritisation	  of	  patient	  safety.	  A	  research	  priority	  list	  compiled	  by	  WHO	  Patient	  Safety	  (39)	  identifies	  inadequate	  competencies	  and	  skills	  as	  well	  as	  the	  lack	  of	  appropriate	  knowledge	  and	  transfer	  among	  the	  top	  six	  research	  priorities	  in	  developed	  and	  developing	  countries.	  
	  These	  research	  priorities	  (39)	  are	  specifically	  appropriate	  for	  the	  transfusion	  of	  blood	  products,	  which	  is	  a	  distinctive	  technology	  that	  blends	  science	  and	  altruism	  (40).	  Modern	  medicine	  has	  a	  continued	  reliance	  on	  blood	  products.	  This	  is	  an	  expensive,	  scarce	  resource	  with	  inherent	  risks	  to	  patients.	  	  It	  is	  therefore	  of	  the	  utmost	  importance	  that	  the	  medical	  profession	  must	  have	  the	  competencies,	  skills	  and	  knowledge	  to	  administer	  blood	  products	  safely	  to	  the	  most	  appropriate	  patients.	  	  In	  this	  chapter	  a	  brief	  history	  of	  blood	  transfusion	  is	  given	  followed	  by	  a	  discussion	  of	  various	  aspects	  of	  blood	  products	  that	  will	  influence	  clinicians’	  competencies,	  skills	  and	  knowledge	  of	  their	  administration.	  These	  aspects	  include	  blood	  product	  safety,	  resources,	  cost,	  ordering,	  administration,	  major	  transfusion	  studies,	  guidelines	  for	  administration,	  physiology,	  alternatives	  to	  blood	  products,	  surveys	  of	  practice,	  effective	  guideline	  implementation	  and	  clinician	  education.	  	  
2.2	  History	  of	  blood	  and	  blood	  product	  transfusion	  
	  The	  history	  of	  blood	  and	  blood	  product	  transfusion	  is	  controversial	  among	  authors	  (41-­‐43).	  A	  brief	  timeline	  is	  elucidated	  below	  but	  may	  be	  in	  dispute	  and	  incomplete.	  The	  evolving	  nature	  and	  safety	  concerns	  of	  blood	  products	  are	  demonstrated:	  
	  
1628:	  William	  Harvey	  discovered	  the	  circulation	  of	  blood	  (42,	  43).	  
1665:	  The	  first	  recorded	  successful	  blood	  transfusion	  occurs	  in	  England.	  Physician	  Richard	  	  Lower	  documents	  a	  dog	  to	  dog	  blood	  transfusion	  (42,	  43).	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1666:	  Edmund	  King	  and	  Richard	  Lower	  together	  claim	  transfusion	  of	  the	  first	  human.	  This	  is	  in	  dispute.	  Jean	  Baptiste	  Denis	  makes	  the	  same	  claim.	  (41-­‐43)	  
1666	  to	  1800s:	  No	  transfusion	  work	  was	  done	  for	  political	  and	  religious	  reasons	  (41-­‐43).	  
1818:	  British	  obstetrician,	  James	  Blundell,	  performs	  the	  first	  successful	  transfusion	  of	  human	  blood	  to	  a	  human	  patient	  for	  the	  treatment	  of	  postpartum	  haemorrhage	  (42,	  43).	  
1907:	  Ludvig	  Hektoen	  suggests	  that	  the	  safety	  of	  transfusion	  might	  be	  improved	  by	  crossmatching	  blood	  between	  donors	  and	  patients	  to	  exclude	  incompatible	  mixtures.	  Reuben	  Ottenberg	  performs	  the	  first	  blood	  transfusion	  using	  blood	  typing	  and	  crossmatching	  (42).	  
1910:	  W.W.	  Duke	  publishes	  the	  first	  documented	  platelet	  transfusion	  (44).	  	  
1914	  to	  1915:	  Long-­‐term	  anticoagulants,	  among	  them	  sodium	  citrate,	  are	  developed,	  allowing	  longer	  preservation	  of	  blood	  (42).	  
1936:	  John	  Elliot	  posits	  the	  use	  of	  plasma	  as	  a	  blood	  substitute	  (45).	  
1940:	  The	  government	  in	  the	  United	  States	  of	  America	  (USA)	  establishes	  a	  national	  blood	  collection	  programme	  (42).	  
1948:	  The	  Red	  Cross	  begins	  the	  first	  nationwide	  blood	  programme	  for	  civilians	  by	  opening	  its	  first	  collection	  centre	  in	  Rochester,	  New	  York	  (42).	  
1954:	  The	  first	  platelet	  transfusions	  are	  shown	  to	  decrease	  mortality	  from	  haemorrhage	  in	  patients	  with	  acute	  leukaemia	  (46).	  
1971:	  Hepatitis	  B	  Virus	  (HBV)	  testing	  of	  donated	  blood	  begins	  (42).	  
1985:	  Red	  Cross	  Blood	  Services	  regions	  begin	  testing	  for	  Human	  Immunodeficiency	  Virus	  (HIV)	  (42).	  
1990:	  Introduction	  of	  first	  specific	  test	  for	  Hepatitis	  C	  Virus	  (HCV)	  (47).	  
2002:	  West	  Nile	  virus	  identified	  as	  transfusion	  transmissible	  (47).	  
2003:	  First	  West	  Nile	  Virus	  positive	  unit	  of	  blood	  intercepted	  (47).	  
2008:	  Four	  probable	  cases	  of	  transmission	  of	  prion	  disease	  via	  blood	  products	  in	  the	  United	  Kingdom	  (48).	  	  
2.3	  Blood	  product	  safety	  
	  Blood	  product	  administration	  carries	  a	  risk	  of	  adverse	  effects.	  These	  include	  infectious	  disease	  transmission	  and	  non-­‐infectious	  complications	  relating	  to	  transfusion	  (23).	  Literature	  states	  that	  certain	  blood	  products	  carry	  higher	  specific	  risks	  than	  others	  but	  figures	  differ	  between	  regions	  (8,	  23,	  24,	  48).	  
• RCC	  has	  an	  increased	  chance	  of	  incompatibility	  reactions	  compared	  with	  other	  blood	  products	  (23,	  24,	  48,	  49).	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• Platelets	  are	  more	  likely	  to	  become	  contaminated	  with	  bacteria	  due	  to	  storage	  at	  room	  temperature	  (8,	  23,	  24,	  48).	  	  
• Plasma	  derived	  products	  like	  FFP	  have	  an	  increased	  chance	  of	  transmitting	  viral	  infections	  and	  causing	  immunologic	  reactions	  when	  compared	  with	  other	  products	  (4,	  5,	  8,	  23,	  24,	  48,	  50).	  	  The	  total	  adverse	  reaction	  rate	  to	  blood	  product	  transfusion	  was	  approximately	  0.24%	  in	  the	  USA	  in	  2009,	  with	  1	  in	  414	  transfusions	  requiring	  a	  diagnostic	  or	  therapeutic	  intervention	  and	  317	  (0.002%)	  life-­‐threatening	  reactions	  (51).	  Serious	  Hazards	  of	  Transfusion,	  the	  United	  Kingdom’s	  haemovigilance	  group,	  received	  1464	  reports	  with	  the	  potential	  for	  mortality	  and	  morbidity	  in	  2010	  (52).	  Among	  these	  there	  were	  13	  deaths	  and	  101	  cases	  of	  major	  morbidity,	  resulting	  in	  a	  serious	  outcome	  for	  7.8%	  of	  cases	  reported.	  Between	  regions,	  large	  discrepancies	  exist	  in	  reports	  on	  transfusion	  reactions	  and	  complications.	  This	  is	  likely	  due	  to	  differences	  in	  reporting.	  The	  reported	  overall	  rates	  from	  various	  sources	  are	  compared	  in	  Table	  2.1.	  (48,	  51-­‐56)	  	  
Table	  2.1	  Comparison	  of	  transfusion	  risks	  by	  region	  (48,	  51-­‐56)	  	  
Type	  of	  Risk	  
	  
Infections	  
Developed	  world	   Developing	  world	  
(Sub-­‐Saharan	  Africa)	  
HIV	   1	  in	  1-­‐4.5	  million	   1	  in	  1000	  	  HBV	   1	  in	  30	  000-­‐200	  000	   4.3	  in	  1000	  HCV	   1	  in	  1-­‐3	  million	   2.5	  in	  1000	  
	  
Immunologic	  Reactions	  
	   	  
Acute	  haemolytic	  reaction	   1	  in	  13	  000	   No	  data	  Delayed	  haemolytic	  reaction	   1	  in	  9000	   No	  data	  Transfusion	  Associated	  Lung	  Injury	   1	  in	  70	  000	   No	  data	  Transfusion	  error	   1	  in	  14000-­‐18000	   No	  data	  	  Up	  to	  3%	  of	  HIV	  infections	  worldwide	  are	  transmitted	  through	  the	  transfusion	  of	  contaminated	  blood	  and	  blood	  products	  (57).	  HBV	  and	  HCV,	  syphilis	  and	  other	  infectious	  agents,	  can	  also	  infect	  recipients	  of	  blood	  products	  (57).	  Emerging	  infectious	  agents,	  including	  prions,	  transmissible	  via	  transfusion,	  continue	  to	  be	  identified	  (54).	  Median	  overall	  risks	  reported	  by	  Jayaraman	  et	  al	  (56)	  of	  becoming	  infected	  with	  HIV,	  HBV	  and	  HCV	  from	  a	  blood	  transfusion	  in	  Sub-­‐Saharan	  Africa	  were	  0,1%,	  0,43%,	  and	  0,25%	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respectively	  according	  to	  a	  mathematical	  model	  although	  the	  completeness	  of	  data	  is	  questioned	  by	  the	  authors.	  	  	  The	  SANBS	  and	  Western	  Province	  Blood	  Transfusion	  Service	  reported	  467	  non-­‐infectious	  adverse	  events	  in	  2009	  representing	  0,05%	  of	  transfusions	  for	  this	  period	  (53).	  One	  case	  of	  HBV	  transmission	  was	  confirmed	  by	  the	  SANBS	  for	  the	  same	  period.	  	  Clinicians	  seem	  to	  be	  aware	  that	  there	  are	  risks	  associated	  with	  blood	  product	  administration	  but	  the	  ability	  to	  quantify	  the	  specific	  risks	  in	  their	  area	  and	  obtain	  informed	  consent	  may	  be	  questioned.	  	  
2.4	  Blood	  product	  resources	  	  Escalating	  costs	  and	  declining	  supply	  of	  blood	  products	  have	  amplified	  the	  pressure	  on	  clinicians	  to	  rationalise	  transfusion	  practice.	  	  The	  WHO	  report	  on	  Universal	  Access	  to	  Safe	  Blood	  Transfusion	  (40)	  highlights	  that	  blood	  transfusion	  is	  a	  crucial	  component	  of	  health	  care.	  Someone	  requires	  blood	  every	  second.	  Artificial	  substitutes	  cannot	  routinely	  replace	  the	  need	  for	  donated	  human	  blood.	  In	  developed	  countries,	  transfusion	  is	  most	  commonly	  used	  to	  support	  innovative	  medical	  and	  surgical	  procedures.	  In	  countries	  where	  diagnostic	  and	  treatment	  options	  are	  limited,	  a	  much	  greater	  proportion	  of	  blood	  is	  used	  to	  treat	  obstetric	  emergencies	  and	  severe	  anaemia,	  often	  resulting	  from	  malaria	  and	  malnutrition.	  	  Whatever	  the	  degree	  of	  development	  of	  health	  care,	  transfusion	  is	  the	  only	  option	  for	  survival	  for	  many	  patients.	  Every	  country	  needs	  to	  meet	  its	  requirements	  for	  blood	  and	  blood	  products	  and	  ensure	  that	  blood	  supplies	  are	  safe.	  Blood	  safety	  is	  fundamental	  for	  the	  achievement	  of	  the	  health-­‐related	  Millennium	  Development	  Goals	  on	  reducing	  child	  mortality,	  improving	  maternal	  health	  and	  combating	  HIV/AIDS.	  (40)	  	  The	  report	  (40)	  concludes:	  “Blood	  transfusion	  is	  a	  distinctive	  technology	  that	  blends	  science	  and	  altruism.	  Though	  its	  collection,	  processing	  and	  use	  are	  technical,	  its	  availability	  depends	  entirely	  on	  the	  selflessness	  of	  the	  blood	  donor	  who	  donates	  this	  precious	  gift.	  “	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2.4.1	  Blood	  products	  in	  South	  Africa	  
	  An	  indication	  of	  blood	  product	  supply	  in	  South	  Africa	  can	  easily	  be	  discovered	  from	  visiting	  the	  SANBS	  website	  (58).	  	  Prominently	  displayed	  on	  the	  homepage	  are	  collections	  and	  target	  fulfilment	  for	  the	  month	  and	  the	  blood	  stock	  level,	  measured	  in	  days,	  inferring	  the	  system	  is	  under	  constant	  pressure.	  	  The	  number	  of	  donations	  has	  increased	  between	  7%	  and	  10%	  since	  2007.	  The	  SANBS	  collected	  790	  258	  units	  of	  blood	  from	  donors	  in	  2009	  (53).	  A	  total	  of	  841	  361	  blood	  products	  were	  issued	  during	  2009	  (53).	  	  	  Clinician	  knowledge	  and	  efficient	  management	  of	  this	  precious	  resource	  is	  enormously	  important	  in	  providing	  health	  care	  delivery	  in	  South	  Africa.	  	  
2.4.2	  Chris	  Hani	  Baragwanath	  Academic	  Hospital	  and	  blood	  products	  	  The	  SANBS	  guideline	  (23)	  is	  supplemented	  by	  the	  United	  Kingdom	  Handbook	  of	  Transfusion	  Medicine	  (24)	  at	  CHBAH	  as	  it	  is	  the	  most	  comprehensive	  guideline	  (59).	  The	  hospital	  does	  not	  have	  a	  major	  surgical	  blood	  ordering	  schedule	  (MSBOS)	  (59).	  There	  is	  however,	  a	  CHBAH	  Local	  Blood	  Committee	  that	  meets	  on	  a	  monthly	  basis	  regarding	  transfusion	  practice,	  costs,	  reporting	  and	  other	  related	  issues	  (59).	  	  In	  2011,	  43	  657	  procedures	  were	  performed	  in	  all	  operating	  theatres	  at	  CHBAH	  (19).	  Between	  5000	  and	  6000	  blood	  products	  are	  ordered	  monthly	  from	  the	  SANBS	  (20).	  Up	  to	  30%	  of	  these	  orders	  are	  cancelled	  or	  wasted	  (20).	  This	  includes	  returned	  units	  that	  must	  be	  discarded	  and	  units	  that	  are	  not	  collected.	  	  	  The	  SANBS	  offers	  the	  option	  of	  ordering	  blood	  on	  returnable	  basis.	  Blood	  is	  transported	  in	  a	  temperature-­‐controlled	  hamper	  as	  seen	  in	  Figure	  2.1.	  Provided	  the	  hamper	  remains	  sealed,	  the	  blood	  is	  returned	  before	  10	  hours	  after	  issue	  and	  remains	  below	  10	  °C,	  it	  will	  be	  accepted	  by	  the	  SANBS	  and	  the	  fee	  for	  blood	  will	  fall	  away.	  Administrative	  and	  service	  fees	  will	  however	  be	  levied.	  (23,	  60)	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Figure	  2.1	  SANBS	  hamper	  
	  
	  
2.5	  Economics	  of	  blood	  products	  
	  Determining	  the	  actual	  costs	  of	  blood	  product	  transfusion	  is	  complex.	  The	  first	  Cost-­‐of-­‐Blood	  Consensus	  Conference	  and	  other	  models	  (61,	  62)	  make	  the	  recommendation	  to	  utilise	  activity	  based	  costing	  methods	  so	  a	  robust	  and	  comprehensive	  evaluation	  can	  be	  made.	  	  The	  actual	  cost	  of	  blood	  to	  individuals,	  health-­‐care	  providers	  and	  society	  is	  difficult	  to	  determine.	  Unless	  all	  contributing	  cost	  elements	  are	  accounted	  for,	  beginning	  with	  blood	  donation,	  continuing	  through	  preparation	  and	  transfusion	  administration	  and	  lasting	  throughout	  long-­‐term	  reporting	  and	  look-­‐back	  programmes,	  the	  cost	  of	  blood	  is	  very	  likely	  to	  be	  miscalculated.	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2.6	  SANBS	  blood	  product	  fees	  
	  The	  2012	  SANBS	  public	  patient	  price	  list	  (60)	  quotes	  the	  prices	  seen	  in	  Table	  2.2	  for	  the	  specified	  services.	  Additional	  fees	  are	  charged	  for	  delivery,	  after	  hour	  service,	  emergency	  request	  and	  administration	  sets	  along	  with	  other	  administrative	  costs.	  Private	  patient	  charges	  are	  20	  to	  25%	  higher	  than	  that	  of	  public	  patients	  (63).	  These	  costs	  are	  the	  charges	  levied	  by	  the	  SANBS,	  which	  clinicians	  should	  consider.	  	  
Table	  2.2	  SANBS	  processing	  and	  blood	  product	  fees.	  (60)	  
Type	  and	  screen	   R	  272.85	  
Crossmatch	   R	  609.33	  
RCC	   R	  1369.39	  
RCC	  (leucocyte	  depleted)	   R	  2237.52	  
Platelet	  concentrate	  (pooled)	   R	  5769.40	  
Platelet	  concentrate	  (pooled	  and	  leucocyte	  depleted)	   R	  7264.02	  
Platelet	  concentrate	  (single	  donor)	   R	  7936.60	  
FFP	  (donor	  retested)	   R	  1095.49	  
FFP	  (cryo-­‐poor	  and	  donor	  retested)	   R	  883.79	  	  
2.7	  Blood	  product	  ordering	  from	  the	  SANBS	  
	  A	  requisition	  form,	  for	  blood	  or	  blood	  components	  outlining	  specific	  patient	  information,	  is	  completed	  by	  a	  clinician	  (23).	  Details	  of	  previous	  medical,	  obstetric	  and	  transfusion	  history	  must	  be	  documented.	  The	  diagnosis,	  reason	  for	  transfusion,	  number	  and	  type	  of	  components	  required	  and	  the	  date	  and	  time	  when	  the	  blood	  or	  blood	  components	  are	  required	  are	  included	  on	  the	  form.	  This	  information	  assists	  the	  SANBS	  staff	  in	  identifying	  the	  recipient	  and	  in	  finding	  compatible	  units	  (23).	  Orders	  for	  platelets	  and	  FFP	  at	  CHBAH	  are	  made	  with	  the	  requisition	  form	  (23).	  A	  patient	  blood	  specimen	  is	  not	  crossmatched	  to	  platelets	  or	  FFP	  unless	  specifically	  requested	  by	  a	  clinician	  at	  CHBAH	  (23).	  	  
2.7.1	  RCC	  ordering	  from	  the	  SANBS	  
	  A	  requested	  type	  and	  screen	  entails	  drawing	  a	  patient	  blood	  specimen	  that	  will	  be	  grouped	  and	  tested	  to	  determine	  blood	  group	  and	  ensure	  that	  it	  does	  not	  contain	  problematic	  antibodies,	  which	  could	  delay	  finding	  compatible	  blood.	  The	  specimen	  will	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be	  held	  for	  96	  hours	  at	  the	  SANBS.	  A	  crossmatch	  confirms	  compatibility	  of	  RCC	  units	  with	  a	  specific	  patient	  specimen.	  A	  standard	  crossmatch	  is	  done	  within	  two	  hours	  by	  the	  SANBS.	  An	  emergency	  crossmatch	  can	  be	  done	  in	  20	  to	  30	  minutes.	  Crossmatched	  products	  will	  be	  held	  in	  reserve	  for	  24	  hours	  unless	  otherwise	  indicated	  by	  the	  attending	  clinician.	  (23)	  	  Two	  small	  studies	  (64,	  65)	  looking	  at	  ratios	  of	  crossmatch	  to	  transfusion	  highlighted	  inefficient	  use	  of	  resources	  showing	  poor	  targeted	  blood	  ordering	  for	  appropriate	  patients	  with	  nearly	  60%	  of	  crossmatched	  units	  not	  transfused.	  Authors	  expressed	  the	  need	  for	  ordering	  guidelines	  in	  each	  facility.	  There	  is	  disparity	  in	  the	  literature	  with	  regard	  to	  procedures	  that	  require	  a	  type	  and	  screen	  or	  crossmatch	  before	  elective	  surgery.	  It	  appears	  to	  be	  a	  challenge	  to	  clinicians	  to	  make	  an	  evidence-­‐based	  decision.	  Clinicians	  at	  CHBAH	  appear	  to	  follow	  similar	  ordering	  patterns	  (20,	  21,	  59,	  66).	  	  	  Guidelines	  suggest	  that	  all	  hospitals	  should	  have	  a	  MSBOS.	  Suggestions	  for	  type	  and	  screen	  have	  been	  recommended	  for	  elective	  surgery	  requiring	  a	  mean	  transfusion	  rate	  of	  0.5	  units	  of	  RCC	  per	  procedure.	  Another	  recommendation	  made	  is	  a	  type	  and	  screen	  being	  done	  for	  procedures	  with	  a	  greater	  than	  5%	  chance	  of	  transfusion.	  This	  represents	  a	  10-­‐fold	  difference	  as	  conveyed	  by	  Dexter	  et	  al	  (67).	  They	  suggest	  a	  new	  approach	  to	  identify	  procedures	  with	  a	  minimal	  estimated	  blood	  loss	  (EBL)	  and	  negate	  the	  need	  for	  a	  type	  and	  screen.	  These	  authors	  claim	  to	  have	  validated	  a	  method	  to	  determine	  whether	  a	  type	  and	  screen	  should	  be	  done	  for	  specified	  procedures.	  This	  complex	  method	  involves	  the	  facility	  determining	  what	  an	  operation’s	  expected	  EBL	  would	  be	  and	  then	  assessing	  a	  number	  of	  procedures	  and	  actually	  measuring	  the	  blood	  loss	  and	  transfusion	  rate.	  A	  large	  incidence	  of	  transfusion	  would	  need	  to	  be	  observed	  for	  a	  procedure	  to	  warrant	  type	  and	  screen.	  The	  authors	  stress	  that	  this	  method	  needs	  to	  be	  implemented	  independently	  and	  recommendations	  should	  differ	  at	  each	  facility.	  (67)	  
	  
2.8	  Administration	  of	  blood	  products	  
	  The	  procedure	  for	  administration	  of	  blood	  products	  may	  vary	  but	  safety	  is	  always	  the	  main	  concern	  (23).	  Informed	  consent	  is	  required	  (23).	  At	  CHBAH	  verbal	  consent	  is	  adequate	  (59).	  The	  unit	  must	  be	  checked	  for	  leaks,	  broken	  seals	  or	  discolouration.	  A	  bedside	  verification	  process	  must	  be	  completed	  according	  to	  the	  SANBS	  guidelines	  (23).	  
• All	  information	  is	  read	  aloud	  by	  two	  qualified	  and	  registered	  attendants	  checking	  the	  blood.	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• The	  recipient’s	  name	  and	  identification	  number	  on	  the	  unit	  must	  be	  identical	  to	  that	  on	  the	  hospital	  record.	  
• The	  identification	  number	  on	  the	  unit	  must	  correlate	  with	  the	  unit	  identification	  number	  on	  the	  requisition	  form	  or	  label.	  
• The	  donor’s	  blood	  groups	  must	  be	  recorded	  on	  the	  blood	  unit.	  
• Verification	  that	  a	  compatibility	  test	  between	  the	  donor	  and	  the	  recipient	  has	  been	  performed	  should	  be	  documented.	  
• If	  possible	  the	  patient’s	  blood	  groups	  should	  be	  confirmed	  from	  previous	  transfusion	  records	  in	  the	  patient’s	  record.	  
• The	  date	  and	  time	  of	  expiry	  of	  the	  unit	  must	  be	  checked.	  Expired	  blood	  must	  not	  be	  transfused.	  If	  any	  abnormalities	  are	  noted	  during	  verification	  the	  product	  should	  not	  be	  transfused	  and	  must	  be	  returned	  to	  the	  SANBS.	  	  If	  a	  transfusion	  reaction	  is	  suspected	  the	  transfusion	  must	  be	  stopped	  immediately,	  the	  administration	  set	  changed	  and	  the	  vein	  kept	  open	  with	  a	  transfusion	  of	  normal	  saline.	  The	  initial	  administration	  set,	  remaining	  blood	  products,	  a	  patient	  blood	  and	  urine	  specimen	  must	  be	  returned	  to	  he	  SANBS.	  A	  complete	  reaction	  report,	  documenting	  the	  reason	  for	  transfusion	  and	  subsequent	  events,	  must	  be	  completed.	  (23)	  	  
2.8.1	  SANBS	  recommendations	  for	  administration	  of	  RCC	  	  
	  RCC	  is	  usually	  transfused	  through	  a	  large	  needle	  or	  cannula,	  the	  size	  of	  which	  is	  selected	  according	  to	  the	  calibre	  of	  the	  patient’s	  veins.	  Meticulous	  attention	  to	  aseptic	  technique	  when	  setting	  up	  the	  transfusion	  is	  important	  to	  avoid	  contamination.	  The	  transfusion	  site	  should	  be	  visible	  through	  a	  transparent	  dressing	  so	  that	  any	  inflammation	  or	  infiltration	  may	  be	  seen	  immediately.	  The	  transfusion	  should	  be	  repositioned	  if	  inflammation	  is	  observed.	  (23)	  	  Baseline	  observations	  of	  vital	  signs	  should	  be	  recorded	  prior	  to	  commencing	  the	  transfusion.	  The	  patient	  is	  then	  observed	  closely	  for	  30	  minutes	  to	  detect	  any	  untoward	  reaction	  and	  to	  ensure	  that	  the	  desired	  rate	  of	  transfusion	  is	  maintained.	  In	  cases	  of	  major	  blood	  loss	  patients	  should	  be	  monitored	  every	  15	  minutes	  throughout	  the	  transfusion.	  In	  less	  severe	  cases	  the	  recipient’s	  vital	  signs	  should	  be	  checked	  every	  half	  hour	  after	  the	  initial	  30	  minute	  observation.	  Patients	  at	  risk	  for	  circulatory	  overload	  should	  be	  observed	  for	  12	  to	  24	  hours	  after	  transfusion.	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The	  rate	  of	  the	  transfusion	  depends	  on	  the	  clinical	  condition	  of	  the	  patient.	  A	  rate	  of	  5	  ml	  per	  minute	  is	  recommended	  for	  the	  first	  30	  minutes	  and	  if	  there	  is	  no	  sign	  of	  untoward	  reaction	  the	  rate	  can	  then	  be	  increased.	  RCC	  transfusions	  must	  be	  completed	  within	  6	  hours.	  (23)	  	  Prevention	  of	  the	  transfusion	  of	  debris	  requires	  use	  of	  70	  –	  240	  μm	  mesh	  filters.	  The	  filter	  should	  be	  covered	  with	  blood	  to	  ensure	  that	  the	  full	  filtering	  area	  is	  used.	  (23)	  	  Blood	  warming	  is	  not	  routinely	  indicated	  and	  refrigerated	  blood	  may	  be	  transfused	  without	  harm	  over	  several	  hours.	  If	  cold	  blood	  is	  administered	  at	  a	  slow	  rate	  it	  does	  not	  appear	  to	  affect	  the	  circulatory	  system.	  However,	  in	  cases	  where	  rapid	  transfusion	  is	  necessary,	  complications	  can	  be	  avoided	  by	  warming	  the	  blood	  to	  not	  more	  than	  37	  °C.	  Overheating	  of	  the	  blood	  can	  cause	  extensive	  haemolysis.	  Blood	  should	  be	  warmed	  with	  a	  blood	  warmer	  specifically	  designed	  for	  this	  purpose.	  (23)	  	  The	  only	  fluids	  that	  can	  be	  given	  concurrently	  through	  the	  same	  intravenous	  device	  as	  a	  red	  cell	  transfusion	  are	  normal	  saline,	  4%	  albumin,	  plasma	  protein	  fractions	  and	  compatible	  plasma	  (23).	  	  
2.8.2	  SANBS	  recommendations	  for	  administration	  of	  platelets	  	  Pooled	  platelets	  should	  be	  transfused	  in	  accordance	  with	  clinical	  guidelines	  (see	  Table	  2.3)	  but	  also	  with	  reference	  to	  an	  individual	  patient's	  clinical	  status.	  A	  peripheral	  smear,	  confirming	  the	  platelet	  count,	  is	  recommended	  before	  administration	  (23).	  The	  platelet	  count	  should	  increase	  by	  20	  to	  60	  x	  109/litre	  per	  standard	  adult	  dose	  containing	  a	  minimum	  of	  2.4	  x	  1011	  pooled	  platelets	  with	  a	  volume	  of	  200	  to	  300mls	  (23,	  25).	  	  Platelets	  are	  never	  refrigerated	  and	  are	  available	  in	  10	  minutes	  (23).	  Platelets	  are	  stored	  with	  continuous	  agitation	  for	  up	  to	  5	  days	  at	  22	  °C	  (23).	  Platelets	  should	  be	  transfused	  immediately	  through	  a	  170	  –	  260	  μm	  filter	  administration	  set,	  specified	  for	  platelet	  use,	  over	  a	  period	  of	  15	  to	  30	  minutes	  at	  room	  temperature	  (23).	  Transfusion	  through	  a	  standard	  red	  cell	  administration	  set	  will	  reduce	  the	  number	  of	  platelets	  received	  (23).	  It	  is	  recommended	  that,	  as	  far	  as	  possible,	  group	  specific	  platelet	  concentrates	  be	  administered	  (23).	  However,	  clinical	  demands	  and	  stock	  availability	  dictates	  that	  patients	  frequently	  receive	  platelet	  transfusions	  that	  are	  not	  blood	  group	  matched	  (23).	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Single	  donor	  platelets	  are	  derived	  from	  one	  donor	  with	  minimum	  yield	  of	  2,4	  x	  1011	  platelets	  and	  a	  volume	  of	  200	  to	  300	  ml.	  Leucocyte	  reduction	  occurs	  during	  an	  apheresis	  procedure;	  therefore	  single	  donor	  platelets	  are	  recommended	  for	  patients	  who	  experience	  febrile	  reactions	  as	  a	  result	  of	  sensitisation	  to	  leucocyte	  antigens.	  Single	  donor	  platelets	  are	  also	  recommended	  for	  patients	  who	  are	  on	  long-­‐term	  platelet	  therapy	  e.g.	  leukaemia.	  (23)	  	  
2.8.3	  SANBS	  recommendations	  for	  administration	  of	  FFP	  	  
	  FFP	  contains	  all	  coagulation	  factors	  at	  near	  normal	  physiological	  levels	  (4,	  6,	  23,	  68).	  	  FFP	  is	  thawed	  from	  frozen,	  typically	  -­‐30	  °C,	  in	  approximately	  40	  minutes	  (23).	  It	  is	  recommended	  to	  thaw	  FFP	  at	  37°C	  (69).	  It	  should	  be	  administered	  through	  a	  blood	  administration	  set	  after	  thawing	  at	  a	  dose	  of	  15	  to	  20	  ml/kg	  (23).	  The	  unit	  should	  be	  transfused	  as	  rapidly	  as	  possible,	  in	  15	  to	  20	  minutes	  per	  unit,	  with	  a	  recommended	  maximum	  delay	  after	  thawing	  of	  up	  to	  four	  hours,	  as	  labile	  coagulation	  factors	  deteriorate	  within	  a	  few	  hours	  of	  thawing	  (23).	  Ideally,	  FFP	  of	  the	  same	  blood	  group	  as	  the	  patient	  should	  be	  administered	  (23).	  If	  this	  is	  not	  available,	  a	  different	  group	  can	  be	  given	  (23).	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AABB	   2012,	  (70)	   7-­‐8	   -­‐	   -­‐	   Consider	  symptoms.	  	  
SIMTI	  Working	  Party	  	  
	  
2011,	  (71)	   <6:	  almost	  always	  require	  transfusion	  6-­‐8:	  in	  presence	  of	  risk	  factors	  or	  symptoms	  8-­‐10:	  in	  presence	  of	  symptoms	  indicating	  hypoxia	  >10:	  rarely	  necessary	  
50:	  surgical	  procedure	   Coagulation	  disorder	  10-­‐15	  ml/kg	  	  
Individual	  risk	  factors	  may	  necessitate	  use	  of	  different	  trigger	  levels.	  	  Assess	  intraoperative	  haemoglobin,	  blood	  loss	  and	  clinical	  parameters.	  
American	  Red	  Cross	  	   2010,	  (72)	   <6:	  transfuse	  6-­‐10:	  as	  per	  indications	  >10:	  transfusion	  not	  necessary	  
10-­‐20	  50-­‐procedures	   Coagulation	  disorder	  10-­‐20	  ml/kg	  
Alter	  guideline	  in	  anticipated	  blood	  loss.	  	  
Napolitano	  et	  al.	   2009,	  (73)	   7	  	   -­‐	   -­‐	   Recommend	  against	  “trigger”	  haemoglobin	  level.	  ACS:	  8	  g/dl.	  
AAGBI	   2008,	  (74)	   7	   -­‐	   -­‐	   	  
SANBS	   2008,	  (23)	   7-­‐8	   10-­‐20	  50-­‐procedures	   Coagulation	  disorder	  15-­‐20	  ml/kg	  
Higher	  in	  presence	  of	  cardiac	  disease.	  6-­‐10	  g/dl	  in	  obstetric	  haemorrhage.	  
NBUGI	   2007,	  (75)	   7	   -­‐	   -­‐	   	  
United	  Kingdom	  
Blood	  services	  
2007,	  (24)	   7	  	   30	  50-­‐100	  for	  procedures	  
Coagulation	  disorder	  15	  ml/kg	  
No	  data	  for	  patients	  with	  ACS.	  9-­‐10	  g/dl	  in	  presence	  of	  ischaemic	  heart	  disease.	  Clinicians	  must	  assess	  for	  adequate	  oxygenation.	  	  
ASA	  Task	  Force	   2006,	  (76)	   Necessary	  below	  6	  Unnecessary	  above	  10	  
50-­‐100	   Coagulation	  disorder	  10-­‐15	  ml/kg	  
Important	  preoperative	  evaluation	  and	  optimisation.	  
BCTMAG	   2003,	  (77)	   7	  	   -­‐	   -­‐	   9	  g/dl	  in	  presence	  of	  cardiac	  disease.	  
ASBT	   2001,	  (78)	   7	  	  	  
10	  -­‐20	  50-­‐procedures	   Coagulation	  disorder	  10-­‐20	  ml/kg	  
Exercise	  clinical	  judgement.	  
AABB:	  American	  Association	  of	  Blood	  Banks;	  SIMTI:	  Italian	  Society	  of	  Transfusion	  Medicine	  and	  Immunohaematology;	  AAGBI:	  Association	  of	  Anaesthetists	  of	  Great	  Britain	  and	  Ireland;	  SANBS:	  South	  African	  National	  Blood	  Service;	  NBUGI:	  National	  Blood	  Users	  Group	  Ireland;	  ASA:	  American	  Society	  of	  Anesthesiologists;	  
BCTMAG:	  British	  Columbia	  Transfusion	  Medicine	  Advisory	  Group;	  ASBT:	  Australasian	  Society	  of	  Blood	  Transfusion;	  ACS:	  acute	  coronary	  syndrome.	  Coagulation	  
disorder	  includes	  specific	  factor	  deficiencies,	  Haemophilia	  A	  and	  B,	  warfarin	  overdose,	  Thrombotic	  Thrombocytopaenic	  Purpura	  (TTP),	  massive	  transfusion	  and	  others.	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2.9	  Landmark	  blood	  product	  studies	  
	  A	  landmark	  trial,	  Transfusion	  Requirements	  In	  Critical	  Care	  (TRICC)	  (1),	  published	  in	  1999,	  directed	  subsequent	  recommendations	  that	  are	  still	  used	  today.	  These	  authors	  hoped	  to	  define	  optimal	  transfusion	  practice	  for	  critically	  ill	  patients	  with	  anaemia.	  A	  restrictive	  approach	  was	  compared	  to	  a	  liberal	  approach	  for	  transfusion.	  Findings	  indicated	  that	  a	  restrictive	  approach,	  consisting	  of	  a	  threshold	  at	  7	  g/dl	  for	  transfusion	  was	  at	  least	  as	  effective	  as,	  and	  possibly	  superior	  to,	  a	  liberal	  transfusion	  strategy,	  consisting	  of	  a	  10	  g/dl	  threshold.	  Haemoglobin	  concentration	  in	  the	  restrictive	  strategy	  was	  maintained	  in	  the	  7	  to	  9	  g/dl	  range	  and	  between	  10	  and	  12	  g/dl	  in	  the	  liberal	  strategy.	  These	  authors	  recommended	  the	  use	  of	  the	  restrictive	  transfusion	  strategy	  for	  all	  critically	  ill	  patients	  with	  the	  exception	  of	  those	  with	  coronary	  ischaemic	  syndromes.	  	  Subsequently,	  the	  Anemia	  and	  Blood	  Transfusion	  in	  the	  Critically	  Ill	  (CRIT)	  study	  (79),	  published	  in	  2004,	  observed	  that	  the	  number	  of	  RCC	  units	  transfused	  is	  an	  independent	  predictor	  of	  a	  worse	  clinical	  outcome	  in	  critically	  ill	  patients.	  Minimising	  transfusion	  exposure	  is	  an	  important	  principle.	  Berger	  et	  al	  (80)	  indicated	  recently	  that	  a	  single	  unit	  transfusion	  policy	  can	  be	  used	  safely	  although	  this	  study	  was	  conducted	  on	  patients	  with	  haematological	  disease.	  	  	  The	  Anaemia	  and	  Blood	  Transfusion	  in	  Critical	  Care	  (ABC)	  investigators	  published	  a	  study	  (81)	  in	  2002	  that	  indicated	  an	  association	  between	  transfusions	  and	  diminished	  organ	  function	  as	  well	  as	  between	  transfusions	  and	  mortality.	  A	  sub-­‐study	  of	  the	  Sepsis	  Occurrence	  in	  Acutely	  Ill	  Patients	  (SOAP)	  study	  in	  2008	  (82)	  did	  not	  confirm	  this	  finding	  despite	  using	  the	  same	  approach	  as	  the	  ABC	  study.	  The	  view	  that	  transfusions	  are	  associated	  with	  an	  increased	  mortality	  rate	  in	  acutely	  ill	  patients	  was	  not	  supported.	  This	  requires	  further	  research	  for	  clarification.	  	  The	  Functional	  Outcomes	  in	  Cardiovascular	  Patients	  Undergoing	  Surgical	  Hip	  Fracture	  Repair	  (FOCUS)	  trial	  (83),	  published	  in	  2011,	  confirmed	  the	  findings	  of	  their	  earlier	  pilot	  study	  (84).	  FOCUS	  was	  designed	  to	  determine	  whether	  patients	  with	  cardiovascular	  disease	  or	  risk	  factors	  undergoing	  surgical	  repair	  of	  hip	  fracture	  benefit	  from	  a	  higher	  or	  lower	  transfusion	  trigger	  specifically	  with	  regard	  to	  functional	  recovery	  and	  new	  cardiac	  events.	  Findings	  were	  in	  keeping	  with	  the	  TRICC	  study	  in	  that	  the	  restrictive	  group	  was	  at	  least	  as	  effective	  as	  a	  liberal	  transfusion	  strategy	  even	  in	  patients	  with	  cardiovascular	  disease	  or	  risk	  factors.	  
	   	   	  23	  
	  In	  2012,	  the	  Cochrane	  Collaboration	  Review	  on	  transfusion	  thresholds	  and	  other	  strategies	  for	  guiding	  allogeneic	  red	  cell	  transfusion	  (2)	  looked	  at	  clinical	  outcomes	  of	  patients	  in	  19	  studies,	  including	  TRICC	  and	  FOCUS,	  comparing	  liberal	  versus	  restrictive	  transfusion	  thresholds	  in	  the	  context	  that	  the	  trends	  in	  current	  guidelines	  favour	  the	  restrictive	  approach	  (see	  Table	  2.3).	  These	  authors	  found	  the	  restrictive	  threshold	  level	  did	  not	  increase	  complication	  rate	  and	  other	  outcome	  measures	  including	  mortality,	  cardiac	  morbidity,	  infections	  and	  length	  of	  hospital	  stay,	  when	  compared	  with	  liberal	  transfusion	  strategies.	  Thus,	  currently	  the	  restrictive	  strategy	  is	  favoured	  by	  this	  review	  despite	  statistically	  significant	  patient	  heterogeneity.	  	  Another	  2012	  Cochrane	  Collaboration	  Review	  (3)	  of	  prophylactic	  platelet	  transfusion	  for	  prevention	  of	  bleeding	  in	  patients	  with	  haematological	  disorders	  concluded	  that	  there	  is	  no	  evidence	  that	  a	  policy	  of	  prophylactic	  platelet	  transfusion	  prevents	  bleeding.	  The	  current	  practice	  of	  using	  a	  platelet	  count	  of	  10	  x	  109/litre	  to	  trigger	  a	  prophylactic	  transfusion	  is	  still	  recommended	  and	  prophylactic	  platelet	  transfusions	  were	  more	  effective	  than	  platelet-­‐poor	  plasma	  at	  preventing	  bleeding	  (3).	  	  Authors	  (4-­‐6,	  68,	  85)	  comment	  on	  the	  lack	  of	  convincing,	  methodologically	  sound	  trials	  to	  outline	  appropriate	  FFP	  use.	  This	  does	  not	  mean	  that	  FFP	  administration	  is	  not	  effective.	  Clinical	  scenarios	  for	  administration	  may	  include:	  
• coagulopathy	  with	  bleeding	  
• coagulopathy	  without	  bleeding	  
• coagulopathy	  without	  bleeding,	  prior	  to	  an	  invasive	  procedure.	  	  In	  a	  2007	  systematic	  review,	  Stanworth	  et	  al	  (5)	  suggests	  FFP	  administration	  has,	  over	  time,	  become	  accepted	  practice	  in	  all	  scenarios	  mentioned	  above.	  These	  practices	  may	  not	  have	  been	  subjected	  to	  the	  clinical	  research	  evaluation	  that	  they	  should	  have	  been.	  The	  need	  for	  appropriately	  powered	  studies	  to	  define	  rational	  use	  of	  FFP	  is	  a	  recurrent	  theme	  in	  papers	  (4-­‐6,	  68,	  85,	  86).	  	  Most	  authors	  and	  published	  guidelines	  urge	  clinicians	  to	  make	  decisions	  to	  transfuse	  in	  a	  clinical	  context	  (2,	  23,	  24,	  70-­‐78).	  Therefore	  this	  process	  should	  demonstrate	  some	  subjectivity.	  However,	  these	  studies	  mentioned	  above,	  as	  well	  as	  recommendations,	  are	  conducted	  with	  patient	  safety	  in	  mind.	  The	  administration	  of	  allogeneic	  blood	  products	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is	  not	  a	  benign	  or	  cheap	  endeavour.	  Striving	  for	  optimum	  patient	  care	  and	  cost-­‐effectiveness	  should	  be	  the	  objective	  of	  all	  involved	  in	  health	  care.	  	  Transfusion	  literature	  specific	  to	  cardiac	  surgery,	  acute	  coronary	  syndromes,	  massive	  transfusion	  and	  chronic	  anaemia	  was	  not	  reviewed	  due	  to	  the	  specialised	  and	  differing	  concerns	  in	  these	  patient	  groups	  and	  is	  not	  discussed	  in	  this	  report.	  	  
2.10	  Blood	  product	  administration	  guidelines	  	  In	  1942	  Adams	  and	  Lundy	  (87)	  advised	  preoperative	  transfusion	  if	  the	  measured	  haemoglobin	  was	  less	  than	  8	  to	  10	  g/dl.	  Confidence	  was	  placed	  in	  these	  numbers	  for	  years	  despite	  a	  lack	  of	  evidence	  supporting	  or	  refuting	  these	  numbers.	  The	  10	  g/dl	  level	  was	  favoured	  at	  the	  time	  based	  on	  physiological	  principles.	  	  Citing	  the	  lack	  of	  clinical	  studies	  around	  the	  physiological	  adaptations	  to	  anaemia	  in	  a	  disease	  state	  in	  1997,	  Hébert	  et	  al	  (88)	  stated	  that	  it	  is	  was	  not	  possible	  to	  offer	  guidelines	  on	  how	  to	  increase,	  maintain	  or	  measure	  optimum	  oxygen	  delivery	  and	  where	  the	  role	  for	  transfusion	  lay	  in	  high-­‐risk	  patients.	  	  	  A	  summary	  of	  various	  current	  guidelines	  is	  given	  in	  Table	  2.3	  for	  completeness.	  Several	  of	  these	  advise	  against	  a	  single	  threshold	  and	  recommend	  a	  range	  between	  6	  and	  10	  g/dl	  depending	  on	  the	  presence	  of	  comorbidity	  (2,	  23,	  24,	  70-­‐78).	  Most	  guidelines	  also	  emphasise	  the	  importance	  of	  a	  clinical	  evaluation.	  	  Guidelines	  for	  platelet	  administration	  are	  also	  mostly	  in	  agreement	  (23,	  24,	  71,	  72,	  76,	  78).	  A	  platelet	  count	  below	  10	  to	  30	  x	  109/litre	  is	  quoted	  as	  requiring	  a	  platelet	  transfusion.	  A	  summary	  of	  prospective	  and	  retrospective	  studies	  confirms	  the	  appropriate	  level	  as	  10	  x	  109/litre	  (8,	  89-­‐91).	  Levels	  of	  50	  x	  109/litre	  for	  surgical	  and	  invasive	  procedures	  and	  100	  x	  109/litre	  for	  ophthalmic	  and	  neurosurgical	  procedures	  are	  recommended	  (23,	  24,	  71,	  72,	  76,	  78,	  91).	  This	  recommendation	  is	  only	  supported	  by	  expert	  opinion	  and	  not	  by	  convincing	  evidence	  according	  to	  Gajic	  et	  al	  (8)	  and	  Arnold	  et	  al	  (92).	  A	  recent	  publication	  (35)	  comparing	  dosages	  of	  prophylactic	  platelet	  transfusions	  in	  preventing	  haemorrhage	  concluded	  the	  platelet	  dose	  has	  no	  significant	  effect	  on	  the	  incidence	  of	  bleeding	  in	  patients	  with	  hypoproliferative	  thrombocytopenia.	  Clinical	  haemostasis	  is	  the	  goal	  of	  treatment	  (91).	  The	  SANBS	  provide	  buffy	  coat	  derived	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platelets,	  from	  five	  donors	  per	  pool,	  suspended	  in	  plasma	  (23).	  This	  is	  equivalent	  to	  one	  adult	  dose.	  	  Prophylactic	  platelet	  transfusion,	  in	  the	  absence	  of	  bleeding,	  occurs	  in	  half	  to	  two	  thirds	  of	  all	  platelet	  administrations	  according	  to	  Arnold	  et	  al	  (92)and	  Greeno	  et	  al	  (90).	  	  A	  2007	  observational	  evaluation	  by	  Cameron	  et	  al	  (89)	  found	  that	  78%	  of	  platelet	  transfusions	  given	  to	  non-­‐surgical	  patients	  were	  administered	  with	  platelet	  counts	  above	  10	  x	  109/litre	  and	  one	  third	  above	  20	  x	  109/litre.	  Additionally	  21%	  of	  transfused	  surgical	  patients	  had	  platelet	  counts	  above	  100	  x	  109/litre.	  	  Clinical	  use	  of	  FFP	  has	  grown	  in	  the	  last	  20	  years	  (4,	  5,	  86).	  Guidelines	  (23,	  24,	  71,	  72,	  76,	  78)	  for	  FFP	  use	  are	  summarised	  in	  Table	  2.3.	  All	  demonstrate	  reasonable	  consensus	  on	  recommendations	  for	  fresh	  frozen	  plasma	  transfusion,	  despite	  the	  lack	  of	  robust	  evidence	  as	  confirmed	  in	  systematic	  reviews	  (4,	  5,	  8,	  68,	  86).	  In	  an	  analysis	  of	  five	  international	  guidelines	  on	  plasma	  by	  Iorio	  et	  al	  (86)	  criticism	  is	  made	  that	  no	  guideline	  is	  complete	  or	  well	  structured.	  	  These	  authors	  recommend	  the	  production	  of	  local	  guidelines	  to	  ensure	  applicability.	  	  A	  coagulation	  defect	  is	  the	  recommended	  indication	  for	  FFP	  administration	  (23,	  24,	  71,	  72,	  76,	  78).	  	  Most	  guidelines	  state	  this	  is	  a	  clinical	  assessment	  of	  a	  coagulopathy	  i.e.:	  evidence	  of	  bleeding	  secondary	  to	  a	  coagulopathy.	  FFP	  is	  not	  recommended	  prophylactically	  for	  correction	  of	  abnormal	  laboratory	  coagulation	  tests	  or	  prior	  to	  invasive	  procedures,	  as	  it	  has	  not	  been	  proven	  in	  this	  setting	  (4,	  5,	  8,	  93).	  Prophylactic	  transfusion	  may	  account	  for	  up	  to	  50%	  of	  administration	  (6,	  7,	  9,	  10).	  	  These	  recommendations	  are	  not	  borne	  out	  in	  clinical	  practice.	  FFP	  appears	  to	  have	  the	  highest	  rate	  of	  inappropriate	  use	  of	  all	  blood	  products	  (4,	  5).	  Great	  variation	  in	  practice	  was	  shown	  in	  2011	  in	  two	  assessments	  of	  current	  use	  in	  the	  United	  Kingdom	  (6,	  7).	  Overall	  FFP	  administration	  is	  not	  rational	  and	  is	  not	  given	  in	  sufficient	  amounts	  (6,	  7,	  9).	  	  Visser	  et	  al	  (11)	  published	  an	  evaluation	  of	  FFP	  use	  in	  2012	  in	  a	  South	  African	  tertiary	  hospital.	  Transfusions	  were	  considered	  inappropriate	  in	  39,5%	  of	  cases.	  The	  authors	  cited	  a	  lack	  of	  knowledge	  regarding	  indications	  for	  FFP	  administration	  and	  stated	  that	  intervention	  is	  necessary	  to	  improve	  rational	  use.	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Clinicians	  appear	  to	  not	  be	  following	  guidelines.	  Most	  clinicians	  and	  authors	  acknowledge	  that	  a	  clinical	  assessment	  is	  important	  in	  the	  decision	  to	  transfuse	  blood	  products	  (12-­‐15).	  Many	  of	  the	  guidelines	  do	  encourage	  this	  practice	  but	  specific	  awareness	  of	  the	  guidelines	  seems	  to	  be	  lacking	  as	  demonstrated	  by	  specific	  questions	  asked	  in	  surveys	  (10,	  12-­‐15).	  	  
2.11	  Physiology	  of	  RCC,	  platelets	  and	  FFP	  	  
	  The	  decision	  to	  administer	  blood	  products	  must	  be	  made	  with	  a	  basic	  understanding	  of	  haematological	  physiology,	  pathophysiology	  and	  the	  physiology	  of	  blood	  product	  administration.	  	  
2.11.1	  Physiology	  of	  haemoglobin,	  anaemia,	  oxygen	  transport	  and	  transfusion	  
	  Red	  cells	  contain	  approximately	  640	  million	  haemoglobin	  molecules.	  Haemoglobin	  is	  the	  molecule	  responsible	  for	  the	  majority	  of	  oxygen	  transport.	  Heme,	  an	  iron-­‐porphyrin	  compound	  is	  joined	  to	  the	  protein	  globin	  consisting	  of	  4	  polypeptide	  chains.	  Oxygen	  is	  bound	  according	  to	  its	  partial	  pressure.	  The	  relationship	  between	  haemoglobin	  and	  oxygen	  is	  demonstrated	  by	  the	  S-­‐shaped	  oxyhaemoglobin	  dissociation	  curve.	  Efficient	  binding	  of	  oxygen	  occurs	  in	  the	  lungs	  at	  a	  high	  partial	  pressure	  and	  unloading	  occurs	  at	  a	  tissue	  level	  where	  there	  is	  a	  low	  partial	  pressure.	  This	  affinity	  can	  be	  altered	  by	  physiological	  adaptive	  mechanisms.	  Haemoglobin	  and	  cardiac	  output	  are	  the	  main	  determinants	  of	  tissue	  oxygenation.	  There	  is	  significant	  physiological	  reserve	  but	  there	  is	  a	  level	  of	  oxygen	  delivery	  below	  which	  demands	  of	  the	  body	  will	  not	  be	  met.	  This	  level	  is	  dependent	  on	  many	  individual	  factors	  such	  as	  age,	  weight,	  metabolic	  demands,	  disease	  states	  and	  other	  factors.	  Adaptations	  occur	  in	  response	  to	  acute	  anaemia	  including	  a	  shift	  of	  the	  oxyhaemoglobin	  curve,	  haemodynamic	  changes	  and	  microcirculatory	  alterations.	  (88,	  94-­‐96)	  	  Acute	  haemorrhage	  can	  result	  in	  hypovolaemia	  and	  anaemia.	  Hypovolaemia	  can	  be	  managed	  with	  intravenous	  fluids	  but	  severe	  anaemia	  is	  usually	  managed	  with	  transfusion	  of	  allogeneic	  red	  cells.	  The	  critical	  level	  of	  haemoglobin	  has	  been	  alleged	  to	  be	  around	  6	  g/dl	  for	  most	  individuals	  (95).	  Red	  cell	  transfusion	  is	  the	  fastest	  way	  of	  raising	  haemoglobin	  and	  has	  saved	  many	  lives	  since	  the	  first	  documented	  transfusion.	  The	  goal	  of	  RCC	  transfusion	  is	  to	  restore	  adequate	  tissue	  oxygenation.	  Whether	  this	  transfused	  blood	  actually	  improves	  tissue	  oxygen	  delivery	  has	  recently	  been	  questioned	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(88).	  Transfusions	  given	  above	  the	  critical	  level	  of	  haemoglobin	  have	  not	  conclusively	  shown	  any	  benefit	  (95).	  The	  clinical	  benefit	  seen	  after	  transfusion	  may	  not	  be	  consequent	  to	  improved	  oxygen	  delivery	  but	  rather	  an	  improvement	  in	  the	  microcirculatory	  milieu	  and	  flow	  mechanics	  (55,	  96).	  It	  is	  still	  unclear	  whether	  storage	  time	  of	  allogeneic	  cells	  has	  adverse	  effects	  for	  the	  recipient	  (97).	  This	  is	  the	  subject	  of	  ongoing	  research.	  	  
2.11.2	  Platelet	  physiology	  
	  Platelets	  or	  thrombocytes	  are	  formed	  in	  the	  bone	  marrow.	  Normal	  levels	  range	  between	  150	  and	  450	  x109/litre.	  Glycoproteins	  on	  the	  surface	  adhere	  to	  injured	  areas	  of	  a	  vessel	  wall	  where	  endothelial	  cells	  are	  damaged	  and	  collagen	  is	  exposed.	  The	  platelet	  membrane	  also	  contains	  large	  amounts	  of	  phospholipid	  that	  activates	  multiple	  stages	  of	  the	  clotting	  cascade.	  Platelets	  have	  a	  half-­‐life	  of	  8	  to	  12	  days.	  (49)	  	  Transfused	  platelets	  should	  function	  as	  normal.	  A	  single	  transfusion	  should	  increase	  the	  platelet	  count	  by	  20	  to	  40	  x	  109/litre	  (23).	  One	  method	  to	  assess	  the	  success	  of	  a	  platelet	  transfusion	  is	  measuring	  the	  absolute	  platelet	  increment	  (91).	  This	  consists	  of	  subtracting	  pretransfusion	  platelet	  counts	  from	  a	  posttransfusion	  measurement	  10	  to	  60	  minutes	  after	  the	  transfusion.	  Prevention	  or	  termination	  of	  haemorrhage	  is	  the	  clinical	  goal.	  	  	  
2.11.3	  Plasma	  and	  coagulation	  
	  Coagulation	  depends	  on	  the	  balance	  between	  procoagualants	  and	  anticoagulants	  normally	  present	  in	  plasma	  (49).	  These	  are	  produced	  mainly	  in	  the	  liver	  and	  vascular	  endothelium	  (49).	  In	  the	  normal	  state	  anticoagulants	  predominate	  so	  that	  circulating	  blood	  does	  not	  clot	  (49).	  When	  a	  vessel	  wall	  is	  damaged	  procoagulants	  in	  the	  area	  become	  activated	  and	  the	  process	  of	  coagulation	  is	  initiated	  (49).	  FFP	  is	  presumed	  to	  contain	  near	  normal	  levels	  of	  coagulation	  factors	  (4,	  6,	  23,	  68).	  	  
2.12	  Alternatives	  to	  blood	  products	  
	  Considerable	  interest	  has	  been	  shown	  in	  the	  range	  of	  products	  and	  interventions	  to	  reduce	  allogeneic	  RCC	  and	  other	  blood	  product	  requirements	  (16-­‐18).	  These	  may	  include:	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• Preoperative:	  
• intravenous	  or	  oral	  iron	  supplementation	  
• erythropoiesis	  stimulating	  agents	  
• autologous	  blood	  donation	  
• designated	  donation.	  
• Intraoperative:	  
• blood	  salvage	  techniques	  
• normovolaemic	  haemodilution	  
• haemostatic	  agents	  
• synthetic	  oxygen	  carriers.	  
• Postoperative:	  
• haemostatic	  agents	  
• intravenous	  or	  oral	  iron	  supplementation	  
• avoidance	  of	  anticoagulants	  and	  antiplatelet	  agents.	  	  Potential	  platelet	  substitutes	  include	  (18):	  
• infusible	  platelet	  membranes	  
• microspheres	  
• cryopreserved	  platelets	  
• lyophilised	  platelets.	  	  Recombinant	  factor	  VIIa	  is	  a	  possible	  FFP	  substitute	  (5).	  	  These	  products	  have	  different	  roles	  to	  play	  and	  are	  proven	  in	  very	  limited	  and	  specific	  circumstances.	  No	  complete	  alternative	  to	  blood	  products	  has	  been	  proven.	  Autologous	  blood	  donation	  is	  increasing	  in	  popularity	  in	  the	  private	  sector	  in	  South	  Africa	  (98).	  	  	  
2.13	  Surveys	  of	  practice	  	  Surveys	  have	  highlighted	  the	  variations	  in	  clinical	  practice	  of	  blood	  product	  transfusion	  despite	  the	  multitude	  of	  available	  guidelines.	  There	  is,	  however,	  paucity	  in	  the	  literature	  with	  regard	  to	  describing	  physicians’	  knowledge	  of	  risks,	  cost,	  appropriate	  ordering,	  administration,	  guidelines	  and	  physiology	  of	  blood	  product	  transfusion.	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Surveys	  conducted	  with	  clinicians	  from	  1987	  to	  2004	  (12,	  14,	  15,	  26)	  have	  shown	  a	  trend	  towards	  the	  accepted	  preoperative	  haemoglobin	  level	  moving	  from	  10	  to	  8	  g/dl.	  No	  absolute	  level	  of	  haemoglobin	  concentration,	  which	  improves	  patient	  safety	  at	  surgery,	  has	  been	  demonstrated	  and	  this	  remains	  controversial	  (88,	  95,	  99).	  	  	  Interestingly,	  Matot	  et	  al	  (15)	  found	  a	  significant	  difference	  in	  lower	  haemoglobin	  limit	  for	  transfusion	  between	  anaesthesiologists	  and	  gynaecologists	  for	  healthy	  patients	  undergoing	  caesarean	  section	  (15)	  in	  their	  2004	  survey:	  7.5	  and	  8	  g/dl	  respectively.	  A	  similar	  difference	  was	  found	  between	  physicians	  and	  surgeons	  treating	  acute	  upper	  gastrointestinal	  bleeding	  by	  Jairath	  et	  al	  (100).	  Matot	  et	  al	  (15)	  also	  commented	  that	  anaesthesiologists	  and	  gynaecologists	  who	  spend	  the	  majority	  of	  their	  time	  in	  obstetrics	  chose	  lower	  transfusion	  thresholds.	  	  Surveys	  of	  treating	  clinicians	  seemed	  to	  show	  a	  marked	  variation	  in	  transfusion	  threshold	  for	  similar	  patients	  (12-­‐15,	  26,	  36,	  100-­‐103).	  This	  is	  most	  markedly	  demonstrated	  by	  Nahum	  et	  al	  (103)	  and	  Lavardière	  et	  al	  (102)	  with	  a	  span	  of	  up	  to	  5	  g/dl	  between	  responses	  in	  the	  paediatric	  critical	  care	  setting.	  Consequently,	  the	  same	  patient	  may	  be	  at	  risk	  of	  tissue	  hypoxia	  due	  to	  undertransfusion	  or	  fluid	  overload	  and	  exposure	  to	  the	  risks	  associated	  with	  overtransfusion.	  The	  authors	  note	  that	  it	  is	  very	  difficult	  to	  recommend	  a	  haemoglobin	  threshold	  for	  transfusion	  to	  the	  critically	  ill	  child.	  This	  variation	  in	  practice	  may	  be	  attributable	  to	  uncertainty.	  	  Differences	  in	  practice	  related	  to	  year	  of	  graduation	  were	  found	  in	  some	  surveys	  (12,	  13,	  26,	  36,	  100).	  Authors	  suggest	  this	  difference	  may	  represent	  teaching,	  guidelines	  or	  consensus	  at	  the	  time	  of	  training.	  One	  study	  reported	  no	  differences	  in	  responses	  among	  clinicians	  with	  differing	  levels	  of	  experience	  (15).	  	  According	  to	  some	  surveys,	  physicians	  seem	  to	  favour	  the	  administration	  of	  at	  least	  two	  units	  of	  red	  cell	  concentrate	  rather	  than	  adopting	  a	  ‘single	  unit	  and	  re-­‐evaluate’	  policy	  (13,	  15,	  101).	  Limited	  knowledge	  of	  the	  amount	  by	  which	  one	  unit	  of	  RCC	  would	  raise	  the	  haemoglobin	  level	  was	  also	  shown	  when	  directly	  asked	  in	  one	  survey	  (26).	  	  When	  asked	  if	  the	  hospital	  at	  which	  they	  worked	  had	  a	  MSBOS,	  40	  to	  50%	  of	  clinicians	  did	  not	  know	  or	  were	  unaware	  of	  the	  availability	  of	  a	  MSBOS	  (12,	  14,	  26).	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The	  question	  of	  transfusion	  and	  related	  immunosuppression	  was	  asked	  in	  two	  surveys.	  Among	  American	  gynaecological	  oncologists	  surveyed	  in	  1995	  (101)	  more	  than	  half	  the	  respondents	  felt	  tumour	  status	  was	  not	  relevant	  in	  the	  decision	  to	  transfuse.	  In	  a	  South	  African	  survey	  published	  in	  1992	  (26)	  more	  than	  half	  of	  respondents	  were	  unaware	  or	  denied	  blood	  product	  transfusion	  can	  be	  immunosuppressive.	  	  	  Clinicians’	  knowledge	  of	  costs	  and	  risks	  associated	  with	  blood	  product	  transfusion	  have	  only	  been	  assessed	  in	  one	  survey	  which	  reported	  a	  poor	  awareness	  of	  these	  (26).	  Questions	  designed	  to	  evaluate	  this	  knowledge	  were	  correctly	  answered	  by	  less	  that	  50%	  of	  respondents.	  	  In	  1992	  Irving	  (26)	  reported	  that	  43%	  of	  surveyed	  clinicians	  indicated	  that	  they	  would	  use	  pooled	  platelets	  with	  a	  measured	  platelet	  level	  above	  50	  x	  109/litre.	  This	  is	  not	  in	  keeping	  with	  the	  recommendations	  in	  guidelines	  (23,	  24,	  71,	  72,	  76,	  78).	  The	  American	  Society	  of	  Anaesthesiologists	  guidelines	  (76)	  state	  that	  platelet	  transfusion	  is	  ineffective	  in	  patients	  with	  idiopathic	  thrombocytopaenic	  purpura.	  Despite	  this,	  55%	  of	  respondents	  to	  Nutall	  et	  al’s	  (14)	  survey	  would	  administer	  platelets	  in	  this	  setting.	  A	  platelet	  counts	  less	  than	  100	  x	  109/litre,	  not	  50	  x	  109/litre,	  was	  also	  indicated	  as	  the	  level	  at	  which	  51%	  of	  anaesthesiologists	  would	  transfuse	  platelets	  in	  this	  study	  (14).	  Educational	  endeavours	  to	  encourage	  closer	  guideline	  implementation	  were	  recommended	  by	  these	  authors	  (14,	  26).	  With	  regard	  to	  prophylactic	  FFP	  transfusion,	  clinicians	  are	  split	  in	  their	  answers.	  There	  is	  demonstrated	  discord	  in	  observed	  practice	  (6,	  7)	  and	  90%	  of	  surveyed	  physicians	  administer	  FFP	  prophylactically	  prior	  to	  an	  invasive	  procedure	  (10).	  Moreover,	  40	  to	  50%	  of	  physicians	  administer	  FFP	  prophylactically,	  citing	  a	  laboratory	  result	  showing	  a	  coagulopathy	  as	  the	  trigger	  (10).	  	  All	  these	  surveys	  demonstrate	  variation	  in	  practice,	  which	  may	  be	  within	  acceptable	  guidelines	  but	  certain	  areas	  of	  knowledge	  and	  protocol	  certainly	  appear	  to	  be	  lacking	  or	  have	  not	  been	  adequately	  assessed.	  However,	  surveys	  assess	  attitudes	  and	  current	  knowledge	  but	  may	  not	  assess	  actual	  practice.	  A	  prospective	  observational	  audit	  may	  be	  a	  better	  assessment	  of	  actual	  practice.	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2.14	  Clinician	  education	  
	  Attempts	  have	  been	  made	  to	  improve	  transfusion	  practices,	  particularly	  those	  that	  aim	  at	  reducing	  unnecessary	  transfusions,	  by	  educating	  clinicians.	  Theoretically	  this	  would	  reduce	  exposure	  to	  risk	  as	  well	  as	  related	  costs.	  Systematic	  reviews,	  looking	  at	  the	  effectiveness	  of	  various	  interventions,	  have	  been	  published	  by	  Tinmouth	  (104)	  in	  2007,	  Tinmouth	  et	  al	  (105)	  	  in	  2005	  and	  Wilson	  et	  al	  (106)	  in	  2002.	  Verlicchi	  (107)	  published	  a	  review	  in	  2010	  on	  evaluating	  the	  clinical	  appropriateness	  of	  blood	  transfusion	  with	  regard	  to	  educational	  tools.	  	  Verlicchi	  (107)	  expressed	  that	  experience	  internationally	  has	  shown	  that	  the	  passive	  dissemination	  of	  recommendations	  and	  guidelines	  is	  ineffective,	  regardless	  of	  the	  importance	  of	  the	  subject.	  The	  author	  describes	  the	  success,	  or	  lack	  thereof,	  of	  various	  educational	  processes	  used	  among	  clinicians.	  
• Distribution	  of	  printed	  educational	  material	  is	  widely	  used	  but	  appears	  to	  have	  limited	  beneficial	  effects	  on	  professional	  practice.	  
• Educational	  meetings,	  conferences	  or	  workshops	  designed	  for	  healthcare	  providers,	  showed	  small,	  if	  any,	  efficacy	  on	  improving	  guideline	  application.	  
• Local	  consensus	  processes	  was	  of	  uncertain	  efficacy.	  
• Educational	  outreach	  visits	  showed	  consistent	  but	  small	  effects.	  
• Local	  opinion	  leaders	  successfully	  reduce	  non-­‐compliance	  with	  clinical	  guidelines	  with	  an	  effect	  comparable	  to	  other	  strategies.	  Identification	  of	  these	  leaders,	  as	  well	  as	  the	  most	  successful	  methods	  to	  obtain	  the	  desired	  results,	  remains	  uncertain.	  
• Audit	  and	  feedback	  is	  the	  most	  widely	  used	  strategy	  to	  improve	  the	  application	  of	  	  	  	  	  	  	  	  guidelines.	  Retrospective	  audits	  are	  summarised	  and	  presented	  to	  a	  group	  of	  individuals	  with	  the	  purpose	  that	  they	  modify	  their	  practice,	  if	  inconsistent	  with	  accepted	  guidelines.	  The	  effectiveness	  has	  been	  shown	  to	  be	  small	  to	  moderate.	  	  Verlicchi	  (107)	  seems	  to	  criticise	  evidence-­‐based	  medicine	  (EBM)	  in	  that	  only	  randomised	  trials	  or	  systematic	  reviews	  constitute	  'evidence'	  and	  the	  definitive	  hierarchy	  of	  this	  evidence	  with	  a	  single	  best	  possibility.	  The	  author	  seems	  to	  favour	  the	  idea	  that	  each	  doctor's	  own	  experience	  and	  reasoning	  can	  be	  used	  to	  manage	  clinical	  practice	  in	  the	  day-­‐to-­‐day	  experience.	  This	  may	  explain	  the	  authors’	  finding	  of	  minimal	  effectiveness	  of	  most	  educational	  interventions.	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Contrasting	  this,	  Tinmouth	  (104),	  Tinmouth	  et	  al	  (105)	  and	  Wilson	  et	  al	  (106)	  suggest	  that	  health	  care	  practitioners’	  transfusion	  practices	  can	  be	  altered	  by	  interventions	  designed	  to	  change	  transfusion	  behaviour	  in	  their	  systematic	  reviews.	  All	  studies	  reviewed	  showed	  an	  effective	  overall	  reduction	  in	  utilisation	  of	  blood	  products	  and	  a	  reduction	  in	  inappropriate	  transfusions	  administered.	  	  	  The	  authors	  mentioned	  above	  (104-­‐106)	  do	  however	  admit	  that	  these	  results	  should	  be	  interpreted	  with	  caution	  due	  to	  the	  heterogeneity	  of	  the	  studies	  examined.	  Statistical	  analyses	  were	  not	  possible	  and	  results	  were	  interpreted	  qualitatively.	  Most	  studies	  are	  also	  more	  than	  10	  years	  old.	  There	  may	  also	  be	  an	  element	  of	  publication	  bias	  in	  that	  studies	  that	  did	  not	  show	  a	  significant	  result	  may	  not	  have	  been	  published.	  No	  cost-­‐benefit	  analysis	  was	  done	  in	  any	  studies.	  No	  studies	  had	  a	  direct	  measurement	  of	  undertransfusion.	  	  Combined	  interventions	  have	  also	  not	  improved	  practice	  and	  a	  return	  to	  baseline	  has	  been	  observed	  following	  completed	  interventions	  and	  during	  ongoing	  interventions	  (104-­‐106).	  In	  Verlicchi’s	  review	  (107)	  he	  describes	  that	  in	  transfusion	  medicine	  prospective	  auditing	  has	  been	  considered	  the	  most	  effective,	  although	  the	  most	  labour-­‐intensive	  intervention,	  because	  it	  takes	  place	  before	  the	  transfusion	  occurs,	  preventing	  inappropriateness	  rather	  than	  merely	  registering	  it.	  The	  surveys	  of	  practice	  conducted	  appear	  to	  demonstrate	  a	  vacuum	  of	  knowledge	  or	  uncertain	  practice.	  Educational	  interventions	  attempted	  appear	  sporadic	  at	  best	  and	  have	  not	  convincingly	  demonstrated	  a	  sustained	  improvement	  in	  transfusion	  practice	  or	  knowledge.	  	  
2.15	  Effective	  guideline	  implementation	  and	  adherence	  among	  clinicians	  	  The	  gap	  between	  clinical	  research	  findings,	  guidelines	  and	  clinical	  practice	  and	  the	  need	  for	  improvement	  has	  been	  well	  demonstrated	  (108-­‐110).	  	  Evidence	  for	  the	  use	  of	  multifaceted	  interventions,	  to	  effectively	  implement	  clinical	  guidelines,	  was	  published	  by	  Prior	  et	  al	  (111)	  in	  a	  systematic	  review.	  The	  data	  set	  precluded	  a	  formal	  statistical	  meta-­‐analysis	  due	  to	  heterogeneity	  of	  studies.	  Interventions	  included	  educational	  outreach,	  educational	  meetings	  and	  interactive	  educational	  interventions,	  clinical	  reminder	  and	  decision	  support	  systems,	  patient-­‐
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specific	  interventions	  and	  the	  production	  of	  simple	  practical	  guidelines.	  Ineffective	  strategies	  included	  didactic	  education	  and	  passive	  dissemination	  strategies	  such	  as	  posting	  the	  guideline	  on	  a	  web	  site,	  or	  providing	  the	  guideline	  to	  clinicians	  in	  printed	  form.	  There	  was	  little	  research	  into	  costs	  of	  guideline	  implementation,	  or	  relative	  costs	  to	  benefits.	  	  A	  recent	  Cochrane	  Collaboration	  Review	  (108)	  of	  the	  effects	  of	  printed	  education	  material	  on	  professional	  practice	  and	  health	  care	  outcomes	  echoes	  what	  Prior	  et	  al	  (111)	  express.	  These	  authors	  confirmed	  that	  the	  best	  method	  of	  information	  dissemination	  remains	  controversial	  and	  is	  dependent	  on	  many	  factors.	  	  A	  1999	  publication	  (112)	  questioning	  why	  physicians	  do	  not	  follow	  clinical	  guidelines	  attempted	  to	  identify	  barriers	  to	  the	  successful	  implementation	  of	  guidelines	  including:	  	  
• lack	  of	  awareness	  of	  guidelines	  
• lack	  of	  familiarity	  with	  the	  guidelines	  
• lack	  of	  agreement	  with	  guidelines	  
• lack	  of	  self	  efficacy	  in	  implementation	  
• lack	  of	  outcome	  expectancy	  
• inertia	  of	  previous	  practice	  
• external	  and	  environmental	  barriers	  to	  guideline	  implementation.	  	  	  Conversely,	  another	  recent	  Cochrane	  Collaboration	  Review	  (110)	  on	  tailored	  interventions	  to	  overcome	  identified	  barriers	  to	  change	  found	  that	  interventions	  tailored	  to	  prospectively	  identified	  barriers	  are	  more	  likely	  to	  improve	  professional	  practice	  than	  no	  intervention	  or	  simple	  distribution	  of	  new	  guidelines.	  The	  methods	  used	  to	  identify	  these	  barriers	  and	  tailor	  interventions	  to	  address	  them	  need	  to	  be	  further	  elucidated.	  	  In	  summary,	  the	  best	  method	  of	  information	  dissemination	  and	  successful	  uptake	  still	  remains	  controversial	  and	  is	  dependent	  on	  many	  factors	  (108,	  111).	  	  
2.16	  Transfusion	  medicine	  education	  at	  CHBAH	  
	  The	  SANBS	  and	  Blood	  Committee	  of	  CHBAH	  host	  a	  blood	  product	  transfusion	  seminar	  annually.	  Attendance	  is	  voluntary	  and	  specific	  topics	  vary.	  Attendees	  complete	  an	  evaluation	  from	  which	  is	  analysed	  by	  the	  SANBS	  (66).	  In	  2011	  about	  half	  of	  respondents	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felt	  that	  the	  purpose	  of	  the	  seminar	  was	  met	  and	  a	  contribution	  to	  capacity	  building	  was	  made	  at	  the	  seminar.	  Only	  61%	  felt	  the	  seminar	  improved	  knowledge	  and	  understanding	  of	  blood	  product	  transfusion	  practice.	  No	  evaluation	  or	  changes	  in	  practice	  as	  a	  result	  of	  this	  seminar	  have	  been	  described	  or	  measured.	  	  Additionally,	  the	  annual	  cardiopulmonary	  resuscitation	  course	  for	  interns	  at	  CHBAH	  provides	  blood	  product	  education	  and	  information.	  SANBS	  guideline	  booklets	  are	  distributed	  to	  all	  interns.	  	  
2.17	  Summary	  
	  From	  the	  literature	  it	  is	  clear	  that	  a	  large	  number	  of	  clinicians	  are	  unaware	  of	  the	  risks,	  cost	  and	  appropriate	  ordering	  of	  blood	  products.	  Despite	  the	  availability	  of	  blood	  product	  administration	  guidelines,	  practice	  falls	  short	  of	  accepted	  recommendations.	  Studies	  looking	  at	  educational	  interventions	  state	  that	  the	  best	  methods	  of	  guideline	  dissemination	  and	  uptake	  remain	  controversial	  and	  are	  dependent	  on	  many	  factors.	  	  
2.18	  Conclusion	  
	  This	  chapter	  discussed	  the	  history	  of	  blood	  transfusion	  followed	  by	  a	  discussion	  of	  various	  aspects	  of	  blood	  products	  that	  will	  influence	  clinicians’	  competencies,	  skills	  and	  knowledge	  of	  their	  administration.	  These	  aspects	  include	  blood	  product	  safety,	  resources,	  cost,	  ordering,	  administration,	  major	  transfusion	  studies,	  guidelines	  for	  administration,	  physiology,	  alternatives	  to	  blood	  products,	  surveys	  of	  practice,	  effective	  guideline	  implementation	  and	  clinician	  education.	  The	  next	  chapter,	  chapter	  3,	  will	  discuss	  the	  research	  methodology	  of	  this	  study.	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Chapter	  3	  -­‐	  Research	  design	  and	  methods	  
	  In	  this	  chapter	  the	  perceived	  situation	  at	  CHBAH	  is	  introduced	  as	  a	  problem	  statement,	  followed	  by	  the	  purpose	  and	  objectives	  of	  this	  research.	  In-­‐depth	  discussion	  of	  the	  ethical	  considerations,	  research	  methodology,	  validity	  and	  reliability	  follow.	  	  
3.1	  Problem	  statement	  
	  CHBAH	  utilises	  the	  services	  of	  the	  SANBS	  to	  provide	  allogeneic	  blood	  products	  for	  use	  on	  patients	  in	  the	  form	  of	  blood	  components.	  Blood	  product	  supply	  is	  in	  high	  demand	  and	  is	  expensive.	  Medical	  doctors	  are	  responsible	  for	  the	  ordering	  and	  prescription	  to	  administer	  blood	  component	  therapy	  at	  CHBAH.	  	  The	  perceived	  situation	  of	  this	  current	  practice	  was	  that	  medical	  personnel	  lack	  the	  competencies,	  skills	  and	  knowledge	  related	  to	  risks,	  cost,	  appropriate	  ordering,	  administration,	  guidelines	  and	  physiology	  of	  blood	  product	  transfusion.	  The	  consequence	  of	  this	  is	  blood	  product	  use	  and	  costs	  are	  not	  optimal	  as	  revealed	  by	  an	  audit	  of	  these	  services	  at	  CHBAH	  (21).	  	  
3.2	  Purpose	  
	  The	  purpose	  of	  this	  research	  was	  to	  describe	  the	  level	  of	  clinicians’	  knowledge	  and	  awareness	  related	  to	  all	  aspects	  of	  the	  ordering	  and	  administration	  of	  blood	  products	  from	  the	  SANBS	  for	  perioperative	  patients	  at	  CHBAH.	  	  
3.3	  Objectives	  
	  The	  primary	  objectives	  of	  this	  study	  were	  to	  determine	  the	  knowledge	  and	  awareness	  of	  clinicians	  with	  regard	  to:	  
• Risks	  associated	  with	  the	  transfusion	  of	  blood	  products.	  
• Resources	  and	  costs	  associated	  with	  the	  transfusion	  of	  blood	  products.	  
• Donations,	  ordering	  and	  return	  of	  blood	  products.	  
• Safe	  administration	  of	  blood	  products	  to	  a	  patient.	  
• Transfusion	  thresholds	  and	  triggers	  for	  blood	  product	  administration.	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The	  secondary	  objectives	  of	  this	  study	  were	  to	  compare	  knowledge	  levels	  among	  the	  different	  specialty	  departments	  and	  clinician	  ranks.	  	  
3.4	  Ethical	  considerations	  
	  Verbal	  assent	  was	  obtained	  from	  the	  Heads	  of	  Departments	  of	  Anaesthesiology,	  General	  Surgery	  and	  Trauma,	  Orthopaedic	  Surgery,	  Obstetrics	  and	  Gynaecology	  and	  the	  Chairman	  of	  the	  CHBAH	  Local	  Blood	  Committee	  prior	  to	  the	  proposal	  being	  submitted	  for	  formal	  approval.	  	  	  Ethics	  approval	  was	  obtained	  from	  the	  Human	  Research	  Ethics	  Committee	  (Medical)	  (Appendix	  1)	  and	  the	  Post-­‐Graduate	  Committee	  of	  the	  University	  of	  the	  Witwatersrand	  (Appendix	  2).	  Subsequently	  consent	  to	  perform	  the	  study	  was	  obtained	  from	  the	  Medical	  Advisory	  Committee	  of	  CHBAH	  (Appendix	  3).	  	  Clinicians	  were	  invited	  to	  take	  part	  in	  the	  study	  and	  were	  given	  a	  self-­‐administered	  questionnaire	  (Appendix	  4).	  The	  questionnaire	  contained	  an	  information	  letter	  (Appendix	  5)	  detailing	  the	  purpose	  of	  the	  study,	  ethics	  and	  CHBAH	  approval.	  The	  agreement	  to	  complete	  the	  questionnaire	  implied	  consent.	  Anonymity	  of	  participants	  and	  questionnaires	  was	  ensured	  by	  not	  recording	  participants’	  names	  on	  the	  questionnaires.	  Completed	  questionnaires	  were	  sealed	  in	  an	  envelope	  and	  placed	  in	  a	  container	  with	  other	  questionnaires.	  Furthermore,	  confidentiality	  was	  ensured	  as	  the	  researcher	  and	  supervisors	  were	  the	  only	  people	  to	  have	  access	  to	  the	  raw	  data.	  	  	  The	  study	  was	  conducted	  in	  adherence	  to	  the	  principles	  of	  the	  Declaration	  of	  Helsinki	  2008	  (33)	  and	  South	  African	  Good	  Clinical	  Practice	  Guidelines	  (34).	  	  
3.5	  Research	  methodology	  
	  
3.5.1	  Research	  design	  
	  A	  prospective,	  descriptive,	  contextual	  study	  design	  was	  used.	  	  	  A	  prospective	  study	  is	  defined	  as	  a	  study	  in	  which	  the	  variables	  will	  be	  measured	  at	  the	  time	  at	  which	  the	  study	  takes	  place	  (35).	  This	  study	  was	  prospective	  in	  that	  a	  group	  of	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clinicians	  were	  identified	  for	  study	  and	  the	  data	  were	  collected	  from	  them	  during	  the	  course	  of	  the	  study.	  	  A	  descriptive	  study	  aims	  to	  describe	  a	  situation	  or	  identify	  problems	  through	  observation,	  description	  or	  classification	  without	  manipulating	  variables	  (35,	  113).	  No	  treatment	  or	  intervention	  is	  tested	  (113).	  This	  study	  was	  descriptive	  in	  design	  in	  that	  it	  planned	  to	  provide	  new	  information	  on	  the	  study	  variables	  defined	  in	  the	  objectives.	  	  A	  contextual	  study	  is	  one	  that	  takes	  place	  in	  a	  specific	  location	  (35).	  This	  study	  was	  contextual	  as	  it	  was	  conducted	  at	  one	  hospital	  only	  –	  CHBAH.	  	  
3.5.2	  Study	  population	  
	  Clinicians	  working	  with	  perioperative	  patients	  in	  the	  Anaesthesiology,	  General	  Surgery	  and	  Trauma,	  Orthopaedic	  Surgery	  and	  Obstetrics	  and	  Gynaecology	  Departments	  belonging	  to	  the	  professional	  levels	  intern,	  medical	  officer,	  registrar	  and	  consultant	  formed	  the	  population	  group	  studied.	  	  
3.5.3	  Study	  sample	  
	  
Sample	  size	  
	  Approximately	  600	  doctors	  are	  employed	  at	  CHBAH	  (32),	  of	  which	  about	  200	  work	  with	  perioperative	  patients	  (32).	  The	  sample	  size	  was	  realised	  by	  the	  number	  of	  respondents	  who	  completed	  the	  questionnaire.	  
	  
Sampling	  method	  
	  All	  members	  within	  the	  departments	  outlined	  were	  identified	  with	  the	  assistance	  of	  the	  departmental	  secretary	  and	  the	  Human	  Resources	  Department.	  A	  convenience	  sampling	  method,	  which	  involves	  the	  selection	  of	  readily	  available	  subjects	  or	  objects	  for	  a	  study	  (35),	  was	  used.	  Clinicians	  working	  at	  CHBAH,	  with	  perioperative	  patients,	  were	  invited	  to	  participate.	  	  Registrars	  on	  the	  University	  of	  the	  Witwatersrand’s	  academic	  circuit,	  rotating	  through	  CHBAH	  at	  the	  time	  of	  the	  study,	  were	  included.	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Inclusion	  criteria	  
	  Clinicians	  from	  the	  Departments	  of	  Anaesthesiology,	  General	  surgery	  and	  Trauma,	  Orthopaedic	  surgery	  and	  Obstetrics	  and	  Gynaecology.	  	  
Exclusion	  criteria	  
• Clinicians	  who	  indicated	  that	  they	  had	  never	  been	  involved	  in	  the	  administration	  of	  blood	  products	  at	  CHBAH.	  
• Clinicians	  who	  declined	  to	  participate.	  
• Clinicians	  on	  annual,	  special	  or	  sick	  leave	  at	  the	  time	  of	  data	  collection	  were	  excluded.	  
3.5.4	  Self-­‐administered	  questionnaire	  
	  
Questionnaire	  development	  
	  In	  order	  to	  develop	  a	  questionnaire	  that	  would	  accurately	  assess	  competencies,	  skills	  and	  knowledge	  related	  to	  blood	  products	  amongst	  clinicians	  the	  literature	  was	  reviewed.	  Terms	  such	  as	  “awareness”,	  “knowledge”,	  “survey”,	  “audit”	  and	  “comfort”	  were	  included	  in	  the	  search.	  A	  few	  of	  the	  studies	  reviewed	  included	  their	  questionnaires	  and	  these	  served	  as	  a	  preliminary	  guide.	  Other	  studies	  did	  not	  include	  their	  questionnaires	  but	  the	  questions	  could	  be	  inferred	  from	  the	  results	  provided.	  	  	  	  Questions	  were	  formulated	  using	  previous	  surveys	  (10,	  12-­‐15,	  26,	  36)	  and	  adapted	  using	  the	  SANBS	  Clinical	  Guidelines	  for	  the	  use	  of	  Blood	  Products	  in	  South	  Africa	  (23).	  	  The	  questionnaire	  assessed	  the	  following:	  
• professional	  rank	  and	  department	  of	  clinicians	  
• knowledge	  of	  risks	  of	  blood	  product	  administration	  
• knowledge	  of	  resources	  and	  costs	  associated	  with	  the	  transfusion	  of	  blood	  products	  
• blood	  product	  	  donation,	  ordering	  and	  return	  
• administration	  of	  blood	  products	  according	  to	  the	  SANBS	  guideline	  (23)	  
• transfusion	  thresholds	  and	  triggers	  for	  blood	  product	  administration	  
• formal	  blood	  product	  education	  attendance.	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  Three	  senior	  anaesthesiologists	  and	  a	  senior	  haematologist,	  all	  with	  blood	  product	  expertise,	  validated	  the	  questionnaire.	  This	  was	  done	  in	  order	  to	  ensure	  validity	  and	  reliability.	  
	  














	   	   	  40	  
	  
	  
Figure	  3.1	  Questionnaire	  design	  and	  administration	  flow	  chart	  	  
	  
	  
3.5.5	  Data	  analysis	  




Face	  validity:	  this	  concept	  is	  an	  assessment	  of	  the	  degree	  to	  which	  a	  research	  tool	  appears	  to	  measure	  what	  it	  is	  intended	  to	  measure.	  Experts	  in	  the	  field,	  based	  on	  their	  intuitive	  judgement,	  assess	  face	  validity	  of	  an	  instrument	  (35).	  In	  this	  study	  the	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questionnaire	  was	  assessed	  and	  validated	  by	  three	  senior	  anaesthesiologists	  and	  a	  senior	  haematologist,	  all	  with	  blood	  product	  expertise.	  	  
Content	  validity:	  this	  concept	  assesses	  how	  well	  the	  research	  tool	  covers	  all	  the	  components	  of	  the	  variable	  it	  proposes	  to	  measure,	  i.e.	  are	  the	  questions	  asked	  representative	  of	  the	  phenomenon	  being	  studied	  (35).	  This	  questionnaire	  was	  developed	  following	  an	  extensive	  literature	  review.	  	  
Criterion-­‐related	  validity:	  this	  concept	  is	  whether	  an	  instrument	  measures	  what	  it	  is	  expected	  to	  measure	  by	  comparing	  it	  to	  another	  measurement	  tool	  that	  is	  known	  to	  be	  valid	  (35).	  Instruments	  used	  in	  similar	  studies	  were	  used	  as	  a	  comparison	  for	  the	  development	  of	  the	  questionnaire.	  	  	  
3.7	  Reliability	  
	  Reliability	  refers	  to	  the	  ability	  of	  a	  study	  or	  a	  study	  instrument	  to	  produce	  consistent,	  reproducible	  results	  if	  used	  over	  time	  or	  by	  different	  investigators	  (35).	  It	  also	  refers	  to	  the	  extent	  to	  which	  independent	  utilisation	  of	  the	  same	  tool	  would	  replicate	  the	  same	  results	  under	  similar	  conditions.	  The	  questionnaire	  was	  developed	  following	  an	  extensive	  literature	  review.	  Having	  the	  questionnaire	  assessed	  by	  three	  senior	  anaesthesiologists	  and	  a	  senior	  haematologist,	  all	  with	  blood	  product	  expertise,	  ensured	  the	  reliability	  of	  the	  research	  tool.	  	  
3.8	  Conclusion	  	  In	  this	  chapter	  the	  perceived	  situation	  at	  CHBAH	  was	  introduced	  as	  a	  problem	  statement,	  followed	  by	  the	  purpose	  and	  objectives	  of	  this	  research.	  In	  depth	  discussion	  of	  the	  ethical	  considerations,	  research	  methodology,	  validity	  and	  reliability	  followed.	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Chapter	  4	  -­‐	  Data	  analysis	  and	  discussion	  of	  results	  
	  
4.1	  Introduction	  	  In	  this	  chapter	  the	  results	  of	  this	  study	  are	  presented	  as	  per	  the	  research	  objectives.	  The	  data	  presented	  include	  demographic	  data	  of	  the	  study	  sample	  and	  the	  knowledge	  and	  awareness	  of	  clinicians	  with	  regard	  to	  blood	  products.	  The	  findings	  are	  described	  and	  analysed	  using	  descriptive	  and	  inferential	  statistics	  and	  percentages	  are	  rounded	  off	  to	  two	  decimal	  places.	  
The	  primary	  objectives	  of	  this	  study	  were	  to	  determine	  the	  knowledge	  and	  awareness	  of	  clinicians	  with	  regard	  to:	  
• risks	  associated	  with	  the	  transfusion	  of	  blood	  products	  
• resources	  and	  costs	  associated	  with	  the	  transfusion	  of	  blood	  products	  
• donations,	  ordering	  and	  return	  of	  blood	  products	  
• safe	  administration	  of	  blood	  products	  to	  a	  patient	  
• transfusion	  thresholds	  and	  triggers	  for	  blood	  product	  administration.	  	  The	  secondary	  objectives	  of	  this	  study	  were	  to	  compare	  knowledge	  levels	  among	  the	  different	  specialty	  departments	  and	  clinician	  ranks.	  	  The	  specific	  questions	  asked	  are	  presented	  before	  the	  results	  for	  each	  objective.	  The	  full	  questionnaire	  and	  answers	  are	  attached	  as	  Appendix	  4.	  	  
4.2	  Results	  	  
4.2.1	  Demographic	  data	  
	  This	  study	  was	  conducted	  at	  CHBAH	  from	  January	  to	  March	  2013.	  Questionnaires	  were	  distributed	  at	  departmental	  academic	  meetings.	  The	  number	  of	  attendees	  had	  been	  estimated	  and	  questionnaires	  were	  distributed	  on	  chairs	  or	  desks	  prior	  to	  meetings.	  	  There	  were	  210	  questionnaires	  distributed	  with	  172	  (81.90%)	  returned.	  Anaesthesiology	  received	  60	  questionnaires	  and	  returned	  56	  (93.33%).	  General	  Surgery	  and	  Trauma	  received	  50	  questionnaires	  and	  returned	  36	  (72%).	  Orthopaedic	  Surgery	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received	  50	  questionnaires	  and	  returned	  40	  (80%).	  Obstetrics	  and	  Gynaecology	  received	  50	  and	  returned	  40	  (80%).	  Blank	  questionnaires	  collected	  from	  desks	  or	  chairs	  after	  the	  meetings	  are	  included	  in	  these	  figures.	  It	  is	  unclear	  whether	  an	  individual	  chose	  not	  to	  complete	  the	  questionnaire	  or	  if	  no	  individual	  was	  seated	  there.	  These	  data	  are	  presented	  in	  Table	  4.1	  	  











Anaesthesiology	   60	   56	  (93.33%)	  
General	  Surgery	  and	  Trauma	   50	   36	  (72%)	  
Orthopaedic	  Surgery	   50	   40	  (80%)	  
Obstetrics	  and	  Gynaecology	   50	   40	  (80%)	  	  Of	  the	  172	  returned	  completed	  questionnaires	  56	  (32.55%)	  were	  from	  Anaesthesiology,	  36	  (20.93%)	  from	  General	  Surgery	  and	  Trauma,	  40	  (23.26%)	  from	  Orthopaedic	  Surgery	  and	  40	  (23.26%)	  from	  Obstetrics	  and	  Gynaecology.	  No	  returned	  questionnaires	  had	  to	  be	  discarded.	  These	  data	  are	  presented	  in	  Table	  4.2	  	  
Table	  4.2	  Completed	  questionnaire	  rate	  
	  Of	  the	  172	  returned	  questionnaires	  49	  (28.49%)	  were	  from	  interns,	  31	  (18.02%)	  were	  from	  medical	  officers,	  57	  (33.14%)	  were	  from	  registrars	  and	  35	  (20.35%)	  were	  from	  consultants.	  	  	  
Department	  
Completed	  questionnaires	  per	  department	  
Total	  =172	  
n	  (%)	  
Anaesthesiology	   56	  (32.55%)	  
General	  Surgery	  and	  Trauma	   36	  (20.93%)	  
Orthopaedic	  Surgery	   40	  (23.26%)	  
Obstetrics	  and	  Gynaecology	   40	  (23.26%)	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In	  the	  last	  two	  years,	  formal	  education	  on	  blood	  products	  was	  attended	  by	  59	  (34.30%)	  respondents.	  No	  formal	  education	  attendance	  was	  reported	  by	  102	  (59.30%)	  respondents	  and	  9	  (5.23%)	  did	  not	  know	  if	  they	  had	  attended	  formal	  education.	  	  Results	  relating	  to	  the	  primary	  objectives	  are	  summarised	  in	  Table	  4.7	  for	  reference	  purposes.	  	  
4.2.2	  Knowledge	  and	  awareness	  of	  clinicians	  with	  regard	  to	  risks	  associated	  with	  
the	  transfusion	  of	  blood	  products	  
	  The	  first	  objective	  of	  this	  study	  was	  assessed	  using	  the	  following	  questions	  with	  multiple-­‐choice	  answers.	  Is	  it	  compulsory	  to	  obtain	  written	  consent	  for	  blood	  product	  transfusion	  at	  your	  hospital?	   	  What	  is	  the	  risk,	  in	  percentage	  per	  transfusion,	  of	  blood	  product	  administration	  in	  South	  Africa?	  
• Infectious	  complication	  e.g.	  HIV	  ?	  
• Non-­‐infectious	  complication	  e.g.	  acute	  haemolytic	  reaction?	  	  The	  most	  common	  cause	  for	  an	  adverse	  transfusion	  reaction	  is?	  	  Is	  blood	  product	  administration	  immunosuppressive?	  
	  Written	  consent	  is	  not	  required	  at	  CHBAH	  for	  blood	  product	  transfusion.	  Currently,	  oral	  consent	  is	  sufficient.	  Fifty-­‐four	  (31.40%)	  respondents	  answered	  this	  correctly,	  108	  (62.79%)	  answered	  incorrectly	  and	  10	  (5.81%)	  respondents	  did	  not	  know	  the	  policy	  at	  CHBAH.	  	  Infectious	  risk	  was	  correctly	  quantified	  by	  108	  (62.79%)	  respondents.	  This	  risk	  was	  overestimated	  by	  31	  (18.02%)	  respondents,	  underestimated	  by	  5	  (2.91%)	  and	  28	  (16.28%)	  did	  not	  know	  the	  infectious	  risk	  percentage.	  Non-­‐infectious	  risk	  was	  correctly	  quantified	  by	  83	  (48.26%)	  respondents.	  This	  risk	  was	  overestimated	  by	  52	  (30.23%),	  underestimated	  by	  2	  	  (1.16%)	  and	  35	  (20.35%)	  respondents	  did	  not	  know	  the	  non-­‐infectious	  risk	  percentage.	  These	  results	  are	  presented	  in	  Table	  4.3	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Table	  4.3	  Knowledge	  of	  risk	  
Risk	  
Correct	  Number	  (n)	  (%)	  
Overestimate	  n	  %	  
Underestimate	  n	  %	  	  
Don’t	  know	  n	  %	  
Infectious	  Risk	  
	  
108	  	  (62.79%)	   31	  	  (18.02%)	   5	  	  (2.91%)	   28	  	  (16.28%)	  
Non-­‐infectious	  
risk	  
83	  	  (48.26%)	   52	  	  (30.23%)	   2	  	  	  (1.16%)	   35	  	  (20.35%)	  
 
     	  Total	  risk,	  for	  infectious	  and	  non-­‐infectious	  complications,	  collectively,	  was	  correctly	  quantified	  by	  66	  (38.37%)	  respondents,	  19	  (22.09%)	  respondents	  got	  both	  incorrect	  and	  24	  (13.95%)	  did	  not	  know	  the	  total	  risk.	  	  Clerical	  and	  laboratory	  error	  were	  identified	  correctly	  as	  the	  main	  reasons	  for	  complications	  arising	  from	  blood	  product	  transfusion	  by	  95	  (55.23%)	  respondents.	  	  A	  total	  of	  52	  (30.23%)	  respondents	  were	  incorrect.	  Of	  these,	  graft	  versus	  host	  disease	  was	  answered	  by	  22	  (12.79%)	  respondents,	  haemolysis	  by	  28	  (16.28%)	  and	  infection	  by	  2	  (1.16%)	  respondents.	  Twenty-­‐five	  (14.53%)	  respondents	  indicated	  that	  they	  did	  not	  know	  the	  main	  reasons	  for	  complications.	  These	  results	  are	  presented	  in	  Table	  4.4	  	  
Table	  4.4	  Clinicians’	  knowledge	  of	  reasons	  for	  complications	  
Ninety-­‐three	  (54.07%)	  respondents	  correctly	  answered	  that	  blood	  product	  transfusion	  is	  immunosuppressive.	  Thirty-­‐one	  (18.02%)	  respondents	  answered	  incorrectly.	  Forty-­‐eight	  (27.91%)	  respondents	  did	  not	  know	  if	  blood	  product	  administration	  is	  immunosuppressive.	  	  
	  	   	  
Correct	  (clerical	  or	  lab	  error)	   95	  (55.23%)	  
	  
Incorrect	  Graft	  versus	  host	  disease	  Haemolysis	  Infection	  
52	  (30.23%)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  22	  (12.79%)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  28	  (16.28%)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  2	  (1.16%)	  
Don’t	  know	   25	  (14.53%)	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4.2.3	  Knowledge	  and	  awareness	  of	  clinicians	  with	  regard	  to	  resources	  and	  costs	  
associated	  with	  the	  transfusion	  of	  blood	  products	  
	  The	  second	  objective	  of	  this	  study	  was	  assessed	  using	  the	  following	  questions	  with	  multiple-­‐choice	  answers.	  What	  is	  the	  approximate	  cost	  of	  the	  following.	  
• One	  unit	  of	  RCC?	  
• One	  unit	  of	  platelet	  concentrate	  (pooled)?	  
• One	  unit	  of	  platelet	  concentrate	  (single	  donor	  apheresis)?	  
• One	  unit	  of	  FFP?	  
• A	  crossmatch?	  
• A	  type	  and	  screen?	  
	  Regarding	  the	  costs	  of	  blood	  products,	  50	  (29.07%)	  respondents	  estimated	  the	  cost	  of	  RCC	  correctly,	  29	  (16.86%)	  estimated	  the	  costs	  of	  pooled	  platelets	  correctly,	  51	  (29.65%)	  respondents	  estimated	  the	  costs	  of	  single	  donor	  platelets	  correctly	  and	  46	  (26.74%)	  estimated	  the	  cost	  of	  FFP	  correctly.	  	  Overestimations	  were	  made	  by	  30	  (17.44%)	  respondents	  regarding	  the	  cost	  of	  RCC,	  38	  (22.09%)	  regarding	  the	  costs	  of	  pooled	  platelets	  and	  89	  (51.74%)	  respondents	  overestimated	  the	  cost	  of	  FFP.	  No	  respondents	  overestimated	  the	  costs	  of	  single	  donor	  platelets.	  	  Underestimations	  were	  made	  by	  80	  (46.51%)	  respondents	  regarding	  the	  cost	  of	  RCC,	  79	  (45.93%)	  regarding	  the	  costs	  of	  pooled	  platelets,	  87	  (50.58%)	  regarding	  the	  costs	  of	  single	  donor	  platelets	  and	  12	  (6.98%)	  respondents	  underestimated	  the	  cost	  of	  FFP.	  	  No	  awareness	  of	  costs	  was	  indicated	  by	  12	  (6.98%)	  respondents	  regarding	  the	  cost	  of	  RCC,	  26	  (15.11%)	  regarding	  the	  costs	  of	  pooled	  platelets,	  34	  (19.77%)	  regarding	  the	  costs	  of	  single	  donor	  platelets	  and	  25	  (14.53%)	  regarding	  the	  cost	  of	  FFP.	  	  Correct	  estimations	  of	  the	  cost	  of	  a	  crossmatch	  were	  made	  by	  14	  (8.14%)	  respondents	  and	  of	  a	  type	  and	  screen	  by	  52	  (30.23%)	  respondents.	  	  Overestimations	  were	  made	  by	  11	  (6.4%)	  respondents	  for	  the	  cost	  of	  a	  crossmatch	  and	  41	  (23.84%)	  for	  the	  cost	  of	  a	  type	  and	  screen.	  	  Underestimations	  regarding	  the	  costs	  of	  a	  crossmatch	  were	  made	  by	  127	  (73.84%)	  respondents	  for	  a	  crossmatch	  and	  39	  (22.67%)	  for	  a	  type	  and	  screen.	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  Costs	  were	  unknown	  by	  20	  (11.63%)	  respondents	  for	  a	  crossmatch	  and	  40	  (23.25%)	  for	  a	  type	  and	  screen.	  These	  data	  are	  represented	  in	  Table	  4.5	  	  
Table	  4.5	  Knowledge	  regarding	  costs	  of	  blood	  products	  and	  associated	  processing	  
Product	  
Correct	  number	  (%)	   Overestimate	  n	  (%)	   Underestimate	  n	  (%)	   Don’t	  know	  n	  (%)	  
RCC	  
	  50(29.07%)	  	   30	  (17.44%)	   80	  (46.51%)	   12	  (6.98%)	  
Pooled	  platelets	   29	  (16.86%)	   38	  (22.09%)	   79	  (45.93%)	   26	  (15.11%)	  
Single	  donor	  
platelets	  
51	  (29.65%)	   0	  (0%)	   87	  (50.58%)	   34	  (19.77%)	  
FFP	   46(26.74%)	   89	  (51.74%)	   12	  (6.98%)	   25	  (14.53%)	  
Crossmatch	   14	  (8.14%)	   11	  (6.4%)	   127	  (73.84%)	   20	  (11.63%)	  
Type	  and	  screen	   52	  (30.23%)	   41	  (23.84%)	   39	  (22.67%)	   40(23.25%)	  	  
4.2.4	  Knowledge	  and	  awareness	  of	  clinicians	  with	  regard	  to	  donations,	  ordering	  
and	  return	  of	  blood	  products	  
	  The	  third	  objective	  of	  this	  study	  was	  assessed	  using	  the	  following	  questions	  with	  multiple-­‐choice	  answers.	  Are	  blood	  donors	  in	  South	  Africa	  voluntary	  and	  non-­‐remunerated?	  Does	  your	  hospital	  utilise	  a	  major	  surgical	  blood	  ordering	  schedule	  (MSBOS)?	  What	  is	  a	  crossmatch?	  What	  is	  a	  type	  and	  screen?	  Are	  you	  aware	  of	  the	  South	  African	  National	  Blood	  Service	  hamper	  system?	  	  Respondents	  correctly	  identified	  blood	  donors	  as	  voluntary	  and	  non-­‐remunerated	  157	  (91.28%)	  times,	  incorrectly	  6	  (3.49%)	  times	  and	  9	  (5.23%)	  respondents	  did	  not	  know.	  	  CHBAH	  does	  not	  utilise	  a	  MSBOS.	  This	  was	  correctly	  answered	  by	  6	  (3.49%)	  respondents,	  87	  (50.58%)	  answered	  incorrectly	  and	  79	  (45.93%)	  did	  not	  know.	  	  Regarding	  processes	  for	  ordering	  blood	  products,	  83	  (48.26%)	  respondents	  defined	  crossmatch	  correctly,	  38	  (22.09%)	  incorrectly	  and	  51	  (29.65%)	  did	  not	  know.	  A	  correct	  definition	  of	  a	  type	  and	  screen	  was	  given	  by	  94	  (54.65%)	  respondents,	  incorrect	  definitions	  by	  50	  (29.07%)	  respondents	  and	  28	  (16.28%)	  respondents	  did	  not	  know.	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Sixty-­‐six	  (38.37%)	  respondents	  were	  aware	  of	  the	  SANBS	  hamper	  system,	  17	  (9.89%)	  were	  unaware	  of	  the	  system	  and	  89	  (51.74%)	  were	  uncertain	  of	  the	  hamper	  system.	  These	  data	  are	  represented	  in	  Table	  4.6	  
	  
Table	  4.6	  Knowledge	  regarding	  donation,	  ordering	  and	  return	  of	  blood	  products	  
	  
Donors	  	  	  number	  (%)	  
MSBOS	  
utilisation	  	  n	  (%)	  
Crossmatch	  	  	  n	  (%)	  
Type	  and	  
screen	  	  n	  (%)	  
Hamper	  
system	  
awareness	  n	  (%)	  
Correct	   157	  (91.28%)	   6	  (3.49%)	   83	  (48.26%)	   94	  (54.65%)	   66	  (38.37%)	  
Incorrect	   6	  (3.49%)	   87	  (50.58%)	   38	  (22.09%)	   50	  (29.7%)	   17	  (9.89%)	  
Don’t	  
know	  
9	  (5.23%)	   79	  (45.93%)	   51	  (29.65%)	   28	  (16.28%)	   89	  (51.74%)	  	  
4.2.5	  Knowledge	  and	  awareness	  of	  clinicians	  with	  regard	  to	  safe	  administration	  of	  
blood	  products,	  transfusion	  thresholds	  and	  triggers	  
	  The	  fourth	  and	  fifth	  objectives	  of	  this	  study	  were	  assessed	  using	  the	  following	  questions	  with	  multiple-­‐choice	  answers.	  At	  what	  temperature/s	  can	  the	  following	  blood	  products	  be	  administered:	  
• RCC?	  
• Platelets?	  
• FFP?	  	  A	  24	  year	  old	  male	  is	  involved	  in	  a	  motor	  vehicle	  accident	  and	  suffers	  severe	  injuries.	  He	  is	  a	  non-­‐smoker	  and	  has	  no	  known	  comorbid	  illness.	  He	  requires	  surgery.	  The	  operation	  is	  accompanied	  by	  profuse	  bleeding.	  He	  is	  resuscitated	  with	  crystalloids.	  He	  does	  not	  exhibit	  a	  volume	  deficit	  and	  the	  bleeding	  is	  now	  controlled.	  At	  what	  haemoglobin	  (in	  g/dl)	  would	  you	  transfuse	  him	  with	  red	  cell	  concentrate?	  	  One	  unit	  of	  packed	  red	  cells	  should	  raise	  the	  haemoglobin	  by	  (in	  g/dl)?	  Assume	  no	  ongoing	  bleeding.	  	  At	  which	  platelet	  count	  (x109/litre)	  would	  you	  administer	  platelet	  concentrate	  to	  prevent	  spontaneous	  bleeding?	  	  One	  mega-­‐unit	  of	  platelets	  should	  normally	  raise	  the	  platelet	  count	  by	  (x109/litre)?	  	  What	  would	  you	  regard	  as	  a	  safe	  platelet	  count	  (x109/L)	  above	  which	  an	  invasive	  or	  surgical	  procedure	  may	  be	  carried	  out?	  	  Under	  what	  circumstances	  do	  you	  administer	  FFP:	  
• Coagulopathy	  with	  bleeding	  due	  to	  clotting	  factor	  deficiency?	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• Abnormal	  laboratory	  clotting	  studies	  with	  no	  clinical	  bleeding	  (no	  history	  of	  a	  bleeding	  diathesis)?	  
• Abnormal	  laboratory	  clotting	  studies	  with	  no	  bleeding	  prior	  to	  a	  procedure	  or	  surgery?	  
• Severe	  burns?	  
• Massive	  transfusion?	  
• Volume	  expansion?	  
• Heparin	  treatment	  reversal?	  
• Warfarin	  treatment	  reversal?	  	  What	  is	  the	  correct	  dose	  of	  FFP	  in	  adults?	  
	  
RCC	  
	  RCC	  can	  be	  administered	  cold,	  at	  body	  temperature	  or	  at	  room	  temperature	  according	  to	  the	  SANBS.	  One	  hundred	  and	  sixty	  eight	  (97.67%)	  answered	  at	  least	  one	  of	  these	  options	  while	  4	  (2.3%)	  respondents	  did	  not	  know	  the	  correct	  temperature	  for	  administration	  of	  RCC.	  	  A	  total	  of	  123	  (71.51%)	  respondents	  correctly	  responded	  to	  the	  haemoglobin	  trigger	  question	  with	  7	  or	  8	  g/dl.	  Respondents	  answered	  7	  g/dl	  65	  (37.80%)	  times	  and	  8	  g/dl	  58	  (33.72%)	  times.	  	  Five	  (2.9%)	  respondents	  answered	  5	  g/dl,	  20	  (11.63%)	  answered	  6	  g/dl,	  9	  (5.23%)	  answered	  9	  g/dl,	  4	  (2.3%)	  answered	  10	  g/dl	  and	  11	  (6.40%)	  were	  unsure.	  These	  data	  are	  represented	  in	  Figure	  4.1	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  Transfusion	  of	  one	  unit	  of	  RCC	  will	  increase	  haemoglobin	  by	  1	  to	  2	  g/dl.	  This	  was	  correctly	  indicated	  by	  156	  (90.69%)	  respondents,	  11	  (6.39%)	  incorrectly	  and	  5	  (2.91%)	  respondents	  did	  not	  know.	  	  
	  
Platelets	  
	  Platelets	  should	  only	  be	  transfused	  at	  room	  temperature.	  This	  was	  correctly	  answered	  by	  90	  (52.32%)	  respondents,	  incorrectly	  by	  74	  (43.02%)	  and	  8	  (4.65%)	  respondents	  did	  not	  know.	  
	  A	  level	  of	  10	  x	  109/litre	  was	  identified	  as	  correct	  for	  transfusion	  of	  platelets	  to	  prevent	  spontaneous	  bleeding	  by	  41	  (23.84%)	  respondents.	  One	  hundred	  and	  twenty	  two	  (70.93%)	  answered	  incorrectly	  and	  9	  (5.23%)	  did	  not	  know.	  	  One	  mega-­‐unit	  of	  platelets	  raising	  the	  platelet	  count	  by	  20	  to	  60	  x	  109/litre	  was	  correctly	  answered	  by	  78	  (45.34%)	  respondents,	  incorrectly	  by	  55	  (31.98%)	  and	  39	  (22.67%)	  did	  not	  know.	  	  A	  safe	  platelet	  count,	  above	  which	  an	  invasive	  or	  surgical	  procedure	  may	  be	  carried	  out,	  was	  correctly	  answered	  as	  50	  x	  109/litre	  by	  82	  (47.67%)	  respondents,	  incorrectly	  by	  83	  (48.26%)	  and	  7	  (4.1%)	  respondents	  were	  unsure.	  	  
FFP	  
	  Transfusion	  of	  FFP	  at	  room	  temperature	  or	  body	  temperature	  was	  correctly	  answered	  by	  143	  (83.14%)	  respondents,	  incorrectly	  by	  22	  (12.79%)	  and	  7	  (4.07%)	  respondents	  did	  not	  know.	  	  The	  appropriate	  indication	  to	  administer	  FFP,	  for	  a	  coagulopathy	  with	  bleeding	  due	  to	  a	  clotting	  factor	  deficiency,	  was	  correctly	  answered	  by	  150	  (87.21%)	  respondents,	  incorrectly	  by	  17	  (9.88%)	  respondents	  and	  5	  (2.90%)	  did	  not	  know.	  	  The	  absence	  of	  an	  indication	  for	  FFP	  administration,	  in	  SANBS	  guidelines,	  for	  abnormal	  laboratory	  clotting	  studies	  with	  no	  clinical	  bleeding	  and	  no	  history	  of	  a	  bleeding	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diathesis	  was	  correctly	  answered	  by	  137	  (79.65%)	  respondents,	  incorrectly	  by	  19	  (11.05%)	  and	  16	  (9.3%)	  did	  not	  know.	  	  The	  lack	  of	  an	  indication,	  in	  SANBS	  guidelines,	  for	  FFP	  administration	  for	  abnormal	  laboratory	  clotting	  studies,	  with	  no	  bleeding	  prior	  to	  a	  procedure	  or	  surgery	  was	  correctly	  answered	  by	  71	  (41.28%)	  respondents,	  incorrectly	  by	  84	  (48.84%)	  and	  17	  (9.88%)	  did	  not	  know.	  	  No	  guideline	  recommends	  FFP	  administration	  in	  severe	  burns.	  This	  was	  correctly	  indicated	  by	  52	  (30.23%)	  respondents,	  incorrectly	  by	  80	  (46.51%)	  respondents	  and	  40	  (23.26%)	  respondents	  did	  not	  know.	  	  The	  indication	  for	  FFP	  administration	  in	  a	  massive	  transfusion	  was	  correctly	  answered	  by	  152	  (88.37%)	  respondents,	  incorrectly	  by	  4	  (2.32%)	  and	  16	  (9.30%)	  did	  not	  know.	  	  The	  incorrect	  use	  of	  FFP,	  purely	  as	  a	  volume	  expander,	  was	  correctly	  identified	  by	  117	  (68.02%)	  respondents,	  incorrectly	  by	  34	  (19.77%)	  respondents	  and	  21	  (12.21%)	  did	  not	  know.	  	  The	  incorrect	  use	  of	  FFP	  for	  heparin	  treatment	  reversal	  was	  correctly	  identified	  by	  99	  (57.56%)	  respondents,	  incorrectly	  by	  46	  (26.74%)	  and	  28	  (16.28%)	  did	  not	  know.	  	  The	  correct	  use	  of	  FFP	  for	  reversal	  of	  warfarin	  treatment	  was	  correctly	  identified	  by	  126	  (73.26%)	  respondents,	  incorrectly	  by	  19	  (11.04%)	  and	  27	  (15.70%)	  did	  not	  know.	  	  The	  correct	  dosage	  of	  FFP	  was	  cited	  by	  66	  (38.37%)	  respondents.	  An	  incorrect	  answer	  was	  given	  by	  39	  (22.67%)	  respondents.	  Of	  these,	  9	  (5.23%)	  respondents	  answered	  one	  unit	  of	  FFP,	  6	  (3.49%)	  with	  two	  units	  of	  FFP,	  17	  (9.88%)	  with	  5	  ml/kg	  and	  7	  (4.07%)	  with	  50	  ml/kg.	  Sixty-­‐seven	  (38.95%)	  indicated	  that	  they	  did	  not	  know	  the	  correct	  dosage.	  
4.2.6	  Summary	  of	  results	  
	  Results	  concerning	  the	  primary	  objectives	  are	  summarised	  in	  Table	  4.7	  for	  reference	  purposes.	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Table	  4.7	  Summary	  of	  results	  
	  
Question	  
Correct	  number	  (%)	   Incorrect	  n	  (%)	   Don’t	  know	  n	  (%)	  




RCC	   50	  (29.07%)	   110	  (63.95%)	   12	  (6.98%)	  Platelets	  (pooled)	   29	  (16.86%)	   117	  (68.02%)	   26	  (15.12%)	  Platelets	  (single	  donor)	   51	  (29.65%)	   87	  (50.58%)	   34	  (19.77%)	  FFP	   46	  (26.74%)	   101	  (58.72%)	   25	  (14.53%)	  Crossmatch	   14	  (8.14%)	   138	  (80.23%)	   20	  (11.63%)	  Crossmatch	  description	   83	  (48.26%)	   38	  (22.09%)	   51	  (29.65%)	  Type	  and	  screen	   52	  (30.23%)	   80	  (46.51%)	   40	  (23.26%)	  Type	  and	  screen	  description	   94	  (54.65%)	   50	  (29.07%)	   28	  (16.28%)	  Donors	   157	  (91.28%)	   6	  (3.49%)	   9	  (5.23%)	  MSBOS	   6	  (3.49%)	   87	  (50.58%)	   79	  (45.93%)	  Hamper	  awareness	   66	  (38.37%)	   Unaware	  17	  (9.89%)	   89	  (51.74%)	  
Temperature	  for	  
administration	  
RCC	   168	  (97.67%)	   0	  (0%)	   4	  (2.33%)	  Platelets	   90	  (52.33%)	   74	  (43.02%)	   8	  (4.65%)	  FFP	   143	  (83.14%)	   22	  (12.79%)	   7	  (4.06%)	  
Haemoglobin	   Trigger	  transfusion	   123	  (71.51%)	   38	  (22.09%)	   11	  (6.39%)	  One	  unit	  RCC	  raise	   156	  (90.7%)	   11	  (6.4%)	   5	  (2.9%)	  
Platelets	   Prevent	  spontaneous	  bleed	   41	  (23.84%)	   122	  (70.93%)	   9	  (5.23%)	  Raise	  platelet	  count	   78	  (45.35%)	   55	  (31.98%)	   39	  (22.67%)	  Administration	  prior	  to	  procedure	   82	  (47.67%)	   83	  (48.25%)	   7	  (4.07%)	  
FFP	   Coagulopathy	  with	  bleeding	   150	  (87.21%)	   17	  (9.88%)	   5	  (2.91%)	  Abnormal	  lab	  test	   137	  (79.65%)	   19	  (11.05%)	   16	  (9.3%)	  Abnormal	  lab	  test	  prior	  to	  procedure	   71	  (41.28%)	   84	  (48.84%)	   17	  (9.88%)	  Severe	  burns	   52	  (30.23%)	   80	  (46.51%)	   40	  (23.26%)	  Massive	  transfusion	   152	  (88.37%)	   4	  (2.32%)	   16	  (9.3%)	  Volume	  expansion	   117	  (68.02%)	   34	  (19.77%)	   21	  (12.21%)	  Heparin	  reversal	   99	  (57.56%)	   46	  (26.74%)	   28	  (16.28%)	  Warfarin	  reversal	   126	  (73.26%)	   19	  (11.05%)	   27	  (15.7%)	  Correct	  dose	   66	  (38.37%)	   39	  (22.67%)	   67	  (38.95%)	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4.3	  Comparison	  of	  knowledge	  levels	  of	  the	  different	  specialty	  departments	  and	  
clinician	  ranks	  
	  The	  secondary	  objectives	  of	  this	  study	  were	  to	  compare	  knowledge	  levels	  among	  the	  different	  specialty	  departments	  and	  clinician	  ranks.	  	  The	  mean	  and	  standard	  deviation	  (SD)	  for	  correctly	  answered	  questions	  was	  16.76	  (4.58)	  from	  32	  questions	  for	  all	  respondents.	  Specialty	  department	  means	  were:	  Anaesthesiology	  19.98	  (3.84),	  General	  Surgery	  and	  Trauma	  16.28	  (4.05),	  Orthopaedic	  Surgery	  13.83	  (4.17)	  and	  Obstetrics	  and	  Gynaecology	  15.63	  (3.51).	  Clinician	  rank	  means	  were:	  interns’	  14.82	  (4.49),	  medical	  officers’	  15.65	  (4.03),	  registrars’	  17.0	  (4.34)	  and	  consultants’	  20.09	  (3.67).	  	  These	  results	  are	  presented	  in	  Tables	  4.8	  and	  4.9	  	  
Table	  4.8	  Questionnaire	  results	  for	  specialty	  departments	  
	   Number	  of	  
respondents	   Mean	  
Standard	  
deviation	  
Anaesthesiology	   56	   19.98	   3.84	  
General	  Surgery	  and	  
Trauma	  
36	   16.28	   4.05	  
Orthopaedic	  Surgery	   40	   13.83	   4.17	  
Obstetrics	  and	  
Gynaecology	  
40	   15.63	   3.51	  
	  	  	  	  	  	  	  	  	  	  	  Total	   172	   16.76	   	  	  	  	  	  	  	  	  	  4.58	  	  







Interns	   49	   14.82	   4.49	  
Medical	  officers	   31	   15.65	   4.03	  
Registrars	   57	   17.0	   4.34	  
Consultants	   35	   20.09	   3.67	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4.3.1	  Specialty	  departments	  
	  After	  consultation	  with	  a	  bio-­‐statistician	  the	  assumptions	  for	  ANOVA	  (equal	  variance	  and	  normality)	  were	  tested	  and	  met.	  ANOVA	  testing	  was	  used	  to	  compare	  means	  between	  specialty	  department	  groups.	  The	  p	  value	  was	  <0.0001,	  therefore	  significant.	  The	  Bartlett	  test	  was	  not	  significant,	  hence	  the	  assumption	  of	  equal	  variances	  across	  specialties	  is	  not	  violated.	  Bonferroni	  testing	  and	  correction	  procedure	  was	  used	  for	  post-­‐testing	  to	  identify	  where	  the	  significant	  differences	  lie.	  A	  p-­‐value	  of	  less	  than	  0.05	  was	  considered	  to	  be	  statistically	  significant.	  	  	  ANOVA	  testing	  did	  identify	  a	  significant	  difference	  between	  specialty	  departments	  and	  with	  Bonferroni	  testing	  Anaesthesiology	  performed	  significantly	  better	  (p=0.000)	  than	  the	  other	  departments.	  No	  significant	  differences	  in	  performance	  were	  demonstrated	  between	  General	  Surgery	  and	  Trauma,	  Orthopaedic	  Surgery	  and	  Obstetrics	  and	  Gynaecology	  (p>0.05).	  This	  is	  presented	  in	  Tables	  4.10	  and	  4.11	  	  
Table	  4.10	  Analysis	  of	  variance	  table	  for	  specialty	  departments	  
Source	  of	  Variation	  
Degrees	  of	  
freedom	  
Sum	  of	  squares	   Mean	  square	  
Treatments	  (between	  
columns)	  
3	   985.87	   328.62	  
Residuals	  (within	  columns)	   168	   2542.0	   15.131	  
Total	   171	   3527.9	   	  
F=	  21.719	  
Bartlett	  statistic	  (corrected)	  =	  1.192	  
p=	  0.7311	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t	  value	   p	  value	  
Anaesthesiology	  vs.	  Obstetrics	  
and	  Gynaecology	  
4.357	   5.411	   <0.001	  
Anaesthesiology	  vs.	  Orthopaedic	  
Surgery	  
6.157	   7.646	   <0.001	  
Anaesthesiology	  vs.	  General	  
Surgery	  and	  Trauma	  
3.704	   4.458	   <0.001	  
Obstetrics	  and	  Gynaecology	  vs.	  
Orthopaedic	  Surgery	  
1.800	   2.069	   >0.05	  
Obstetrics	  and	  Gynaecology	  vs.	  
General	  Surgery	  and	  Trauma	  
-­‐0.6528	   0.7305	   >0.05	  
Orthopaedic	  Surgery	  vs.	  General	  
Surgery	  and	  Trauma	  
-­‐2.453	   2.745	   >0.05	  
	  
4.3.2	  Clinician	  rank	  
	  After	  consultation	  with	  a	  bio-­‐statistician	  the	  assumptions	  for	  ANOVA	  (equal	  variance	  and	  normality)	  were	  tested	  and	  met.	  ANOVA	  testing	  was	  used	  to	  compare	  means	  between	  ranks	  of	  clinicians.	  The	  p	  value	  was	  <0.0001,	  therefore	  significant.	  The	  Bartlett	  test	  was	  not	  significant,	  hence	  the	  assumption	  of	  equal	  variances	  across	  ranks	  was	  not	  violated.	  Bonferroni	  testing	  and	  correction	  procedure	  was	  used	  for	  post-­‐testing	  to	  identify	  where	  the	  significant	  differences	  lie.	  A	  p-­‐value	  of	  less	  than	  0.05	  was	  considered	  to	  be	  statistically	  significant.	  	  	  ANOVA	  testing	  did	  identify	  a	  significant	  difference	  between	  clinician	  ranks.	  With	  Bonferroni	  testing	  consultants	  performed	  better	  than	  other	  ranks	  (p<0.005).	  Interns,	  medical	  officers	  and	  registrars	  performed	  similarly	  with	  no	  significant	  difference	  between	  them	  demonstrated	  (p>0.005).	  This	  is	  presented	  in	  Tables	  4.12	  and	  4.13	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3	   614.04	   204.68	  
Residuals	  (within	  
columns)	  
168	   2969.2	   17.674	  
Total	   171	   3583.2	   	  
F=11.581	  
Bartlett	  statistic	  (corrected)	  =	  1.78	  
p=0.6193	  
	  




T	  value	   P	  value	  
Consultants	  vs.	  registrars	   3.086	   3.418	   <0.001	  
Consultants	  vs.	  medical	  officers	   4.441	   4.283	   <0.001	  
Consultants	  vs.	  interns	   5.269	   5.664	   <0.001	  
Registrars	  vs.	  medical	  officers	   1.355	   1.444	   >0.05	  
Registrars	  vs.	  interns	   2.184	   2.666	   >0.05	  
Medical	  officers	  vs.	  interns	   0.8288	   0.8591	   >0.05	  	  
4.4	  Discussion	  
	  The	  safety	  of	  blood	  products,	  obtained	  from	  the	  SANBS,	  appear	  to	  be	  on	  a	  par	  with	  international	  standards	  and	  are	  certainly	  the	  safest	  in	  Sub-­‐Saharan	  Africa	  (48,	  51-­‐56).	  However,	  risks	  are	  not	  completely	  eliminated	  and	  clinicians’	  knowledge	  of	  the	  risks	  associated	  with	  blood	  product	  administration	  appears	  to	  be	  poor	  with	  only	  38.37%	  of	  respondents	  able	  to	  accurately	  quantify	  both	  the	  infectious	  and	  non-­‐infectious	  risk.	  Just	  over	  half	  of	  respondents	  identified	  the	  most	  common	  cause	  of	  an	  adverse	  reaction	  to	  blood	  product	  transfusion	  as	  clerical	  or	  laboratory	  error	  and	  a	  similar	  number	  appreciated	  that	  blood	  product	  administration	  is	  immunosuppressive.	  These	  findings	  are	  similar	  to	  Irving’s	  South	  African	  survey	  published	  in	  1992	  (26)	  with	  30	  to	  60%	  of	  respondents	  able	  to	  appropriately	  quantify	  risks	  of	  blood	  product	  transfusion.	  Knowledge	  and	  the	  ability	  to	  quantify	  the	  complications	  of	  blood	  product	  use	  are	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required	  to	  obtain	  informed	  consent.	  The	  results	  of	  this	  study	  bring	  into	  question	  the	  ability	  of	  clinicians	  to	  obtain	  informed	  consent.	  	  Poor	  awareness	  of	  costs	  was	  also	  demonstrated	  with	  approximately	  half	  of	  all	  respondents	  overestimating	  costs	  of	  FFP,	  underestimating	  costs	  of	  RCC	  and	  platelets	  and	  73.84%	  underestimating	  the	  cost	  of	  a	  crossmatch.	  Previous	  surveys	  have	  not	  directly	  assessed	  knowledge	  of	  blood	  product	  costs.	  	  	  With	  regard	  to	  donations,	  ordering	  and	  return	  of	  blood	  products	  to	  the	  SANBS	  91.28%	  of	  respondents	  correctly	  stated	  that	  donors	  are	  voluntary	  and	  non-­‐remunerated.	  A	  lack	  of	  understanding	  of	  the	  definitions	  and	  difference	  between	  a	  crossmatch	  and	  a	  type	  and	  screen	  was	  shown	  with	  only	  48.26%	  defining	  a	  crossmatch	  correctly	  and	  54.65%	  defining	  a	  type	  and	  screen	  correctly.	  Respondents	  indicating	  that	  they	  did	  not	  know	  these	  definitions	  numbered	  29.65%	  and	  16.28%	  respectively.	  	  	  Between	  40	  and	  60%	  of	  anaesthesiologists,	  working	  in	  the	  USA,	  surveyed	  in	  1987	  (12)	  required	  that	  blood	  be	  crossmatched	  for	  certain	  procedures	  indicating	  the	  variation	  in	  practice	  at	  the	  time.	  The	  alternative	  option	  of	  a	  type	  and	  screen	  was	  not	  assessed.	  Comments	  in	  a	  2003	  survey	  of	  members	  of	  the	  American	  Society	  of	  Anesthesiologists	  (14)	  seem	  to	  indicate	  that	  these	  respondents	  knew	  the	  difference	  between	  a	  crossmatch	  and	  a	  type	  and	  screen	  but	  cited	  delays	  in	  obtaining	  blood	  products	  when	  a	  type	  and	  screen	  was	  requested	  and	  therefore	  a	  crossmatch	  was	  preferentially	  requested.	  The	  rationality	  of	  crossmatching	  blood	  was	  assessed	  by	  two	  studies	  (64,	  65)	  and	  a	  more	  protocol-­‐based	  approach	  to	  optimise	  RCC	  ordering	  is	  suggested.	  These	  studies	  (12,	  14,	  64,	  65)	  did	  not	  directly	  question	  respondents’	  knowledge	  of	  the	  difference	  between	  a	  crossmatch	  and	  a	  type	  and	  screen.	  CHBAH	  does	  not	  utilise	  a	  MSBOS	  but	  knowledge	  and	  appropriate	  application	  of	  the	  system	  in	  previous	  studies	  (12,	  14,	  26,	  65,	  114)	  was	  poor.	  Awareness	  of	  the	  SANBS	  hamper	  system	  was	  only	  demonstrated	  by	  38.37%	  of	  respondents.	  	  It	  would	  seem	  respondents’	  knowledge	  of	  RCC	  is	  better	  than	  that	  of	  platelets	  and	  FFP	  with	  97.67%	  of	  respondents	  indicating	  an	  acceptable	  transfusion	  temperature,	  71.51%	  indicating	  an	  appropriate	  haemoglobin	  level	  transfusion	  trigger	  of	  7	  to	  8	  g/dl	  and	  90.69%	  stating	  that	  a	  single	  unit	  of	  RCC	  would	  raise	  the	  haemoglobin	  by	  1	  to	  2	  g/dl.	  The	  trend	  of	  accepting	  a	  lower	  haemoglobin,	  as	  in	  previous	  surveys	  (12-­‐15,	  26,	  36,	  100,	  101,	  114),	  appears	  to	  be	  sustained	  and	  is	  reflected	  in	  this	  study.	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  Platelet	  knowledge	  was	  not	  as	  robust	  with	  23.84%	  of	  respondents	  correctly	  stating	  a	  level	  of	  10	  x	  109/litre	  at	  which	  to	  transfuse	  platelets	  to	  prevent	  spontaneous	  bleeding,	  45.34%	  stating	  correctly	  that	  one	  mega-­‐unit	  would	  raise	  a	  platelet	  count	  by	  20	  to	  60	  x	  109/litre,	  47.67%	  correctly	  identifying	  a	  platelet	  count	  of	  50	  x	  109/litre	  as	  a	  safe	  cut	  off	  for	  surgery	  and	  the	  correct	  platelet	  transfusion	  temperature	  cited	  by	  52.32%	  of	  respondents.	  	  Previous	  audits	  and	  surveys	  of	  platelet	  transfusion	  triggers	  (10,	  14,	  26,	  90,	  92)	  also	  demonstrated	  poor	  adherence	  to	  guidelines.	  In	  these	  studies	  anywhere	  between	  20	  and	  75%	  of	  platelet	  transfusions	  were	  in	  accordance	  with	  guidelines	  at	  the	  time	  and	  most	  platelet	  transfusions	  are	  administered	  to	  prevent,	  rather	  than	  treat,	  bleeding.	  	  Clinical	  use	  of	  FFP	  has	  grown	  in	  the	  last	  20	  years	  (4,	  5,	  86).	  Guidelines	  (23,	  24,	  71,	  72,	  76,	  78)	  demonstrate	  consensus,	  although	  vague,	  on	  recommendations	  for	  fresh	  frozen	  plasma	  transfusion,	  despite	  the	  lack	  of	  strong	  evidence	  as	  confirmed	  in	  systematic	  reviews	  (4,	  5,	  8,	  68,	  86).	  Criticism	  can	  be	  made	  that	  no	  guidelines	  are	  complete	  and	  authors	  recommend	  the	  production	  of	  local	  guidelines	  to	  ensure	  applicability.	  	  A	  coagulation	  defect	  is	  the	  recommended	  indication	  for	  FFP	  administration	  (23,	  24,	  71,	  72,	  76,	  78).	  	  Most	  guidelines	  state	  this	  is	  a	  clinical	  assessment	  of	  a	  coagulopathy	  i.e.:	  evidence	  of	  bleeding	  secondary	  to	  a	  coagulopathy.	  FFP	  is	  not	  recommended	  prophylactically	  for	  correction	  of	  abnormal	  laboratory	  coagulation	  tests	  or	  prior	  to	  invasive	  procedures,	  as	  it	  has	  not	  been	  proven	  in	  this	  setting	  (4,	  5,	  8,	  93).	  	  	  In	  this	  study	  respondents	  answers	  to	  questions	  based	  on	  FFP	  use	  were	  compared	  to	  the	  SANBS	  guideline	  (23)	  and	  the	  United	  Kingdom	  Handbook	  of	  Transfusion	  Medicine	  (24).	  The	  appropriate	  use	  of	  FFP	  for	  coagulopathy	  with	  bleeding	  due	  to	  clotting	  factor	  deficiency,	  massive	  transfusion	  and	  reversal	  of	  warfarin	  treatment	  was	  correctly	  answered	  by	  87.21%,	  88.37%	  and	  73.26%	  of	  respondents	  respectively.	  Temperature	  for	  administration	  and	  dosing	  of	  FFP	  are	  outlined	  in	  guidelines	  and	  83.14%	  and	  38.37%	  of	  respondents,	  respectively,	  were	  in	  line	  with	  recommendations.	  Inappropriate	  FFP	  administration	  for	  heparin	  treatment	  reversal	  was	  correctly	  identified	  by	  57.56%	  of	  respondents.	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The	  following	  indications	  for	  FFP	  are	  not	  recommended	  in	  guidelines	  and	  are	  not	  evidence-­‐based.	  These	  were	  therefore	  assessed	  as	  incorrect,	  if	  identified	  as	  an	  indication	  for	  administration,	  although	  clinical	  scenarios	  may	  certainly	  warrant	  administration.	  	  Responses	  compared	  with	  guidelines	  were	  as	  follows.	  
• FFP	  is	  not	  indicated	  in	  abnormal	  laboratory	  clotting	  studies	  with	  no	  clinical	  bleeding	  and	  no	  history	  of	  a	  bleeding	  diathesis	  -­‐	  79.65%	  of	  respondents	  correct.	  
• FFP	  is	  not	  indicated	  in	  abnormal	  laboratory	  clotting	  studies	  with	  no	  bleeding	  prior	  to	  a	  procedure	  or	  surgery	  -­‐	  41.28%	  of	  respondents	  correct.	  
• FFP	  is	  not	  indicated	  in	  severe	  burns	  -­‐	  30.23%	  of	  respondents	  correct.	  
• The	  inappropriate	  use	  of	  FFP,	  purely,	  as	  a	  volume	  expander	  -­‐	  68.02%	  of	  respondents	  correct.	  	  Respondents’	  answers	  with	  regard	  to	  FFP	  use	  were	  similar	  to	  previous	  reports	  where	  FFP	  appears	  to	  have	  the	  highest	  rate	  of	  inappropriate	  use	  of	  all	  blood	  products	  (4,	  5).	  Large	  variations	  in	  practice	  were	  shown	  in	  three	  assessments	  of	  current	  use	  of	  plasma	  in	  the	  United	  Kingdom	  and	  South	  Africa	  (6,	  7,	  11).	  These	  authors	  cited	  lack	  of	  knowledge	  regarding	  indications	  for	  FFP	  administration	  and	  stated	  that	  intervention	  is	  necessary	  to	  improve	  rational	  use.	  	  In	  this	  study	  respondents	  from	  Anaesthesiology	  performed	  better	  than	  their	  colleagues	  (p=0.000)	  with	  a	  mean	  19.98	  (3.84)	  correct	  answers,	  although	  overall	  results	  remain	  disappointing.	  There	  were	  no	  significant	  differences	  in	  performance	  of	  General	  Surgery	  and	  Trauma,	  Orthopaedic	  Surgery	  and	  Obstetrics	  and	  Gynaecology	  (p>0.005).	  Perhaps	  the	  better	  performance	  demonstrated	  by	  Anaesthesiology	  respondents	  can	  be	  attributed	  to	  observing	  a	  clinical	  response	  to	  administration	  of	  blood	  products	  acutely	  with	  patient	  monitoring.	  	  Among	  the	  clinician	  ranks,	  consultants	  performed	  significantly	  better	  	  (p≤0.005)	  than	  their	  junior	  colleagues	  with	  a	  mean	  20.09	  (3.67)	  correct	  answers.	  This	  is	  almost	  certainly	  due	  to	  experience.	  	  When	  compared	  with	  previous	  surveys	  and	  audits	  (10,	  12-­‐15,	  26,	  36,	  65,	  100-­‐103,	  115,	  116)	  the	  results	  of	  this	  study	  are	  certainly	  comparable	  and	  similarly	  discouraging.	  	  Comparing	  these	  results	  to	  those	  of	  the	  only	  previous	  South	  African	  survey	  (26),	  conducted	  in	  1992,	  overall	  performance	  is	  similar	  although	  there	  are	  differences	  between	  questions	  asked.	  Areas	  in	  which	  respondents	  appear	  to	  have	  performed	  better,	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or	  at	  least	  in	  accordance	  with	  current	  guidelines,	  are	  haemoglobin	  triggers	  for	  RCC	  transfusion,	  response	  to	  RCC	  administration	  and	  massive	  transfusion	  protocols.	  Knowledge	  of	  risks,	  costs,	  platelet	  and	  FFP	  use	  are	  similarly	  disheartening.	  	  In	  the	  last	  two	  years	  formal	  education	  on	  blood	  products	  had	  been	  attended	  by	  34.30%	  of	  respondents.	  The	  CHBAH	  annual	  seminar	  (66)	  is	  the	  most	  likely	  setting	  for	  this	  education.	  No	  evaluation	  or	  changes	  in	  practice	  as	  a	  result	  of	  the	  seminars	  have	  been	  described	  or	  measured.	  Previous	  studies	  (104-­‐107)	  differ	  in	  reporting	  success	  with	  different	  educational	  interventions	  including	  lectures,	  meetings,	  printed	  materials	  and	  audits.	  Other	  authors	  (108-­‐112)	  posit	  reasons	  why	  clinicians	  do	  not	  follow	  guidelines.	  This	  study	  did	  not	  explore	  reasons	  for	  the	  apparent	  poor	  knowledge	  or	  whether	  guidelines	  are	  actually	  implemented.	  
	  
4.5	  Conclusion	  
	  Clinicians’	  knowledge	  of	  risks,	  resources,	  costs,	  ordering	  and	  return	  of	  blood	  products	  is	  discouraging.	  Disturbing	  trends	  appear	  to	  be	  common	  and	  in	  dispute	  with	  some	  local	  and	  international	  guidelines.	  Of	  particular	  concern	  is	  the	  lack	  of	  appropriate	  knowledge	  to	  obtain	  informed	  consent	  and	  the	  lack	  of	  guidance	  with	  regard	  to	  FFP	  administration.	  	  It	  could	  be	  argued	  that	  knowledge	  of	  costs	  is	  inconsequential	  if	  blood	  products	  are	  used	  appropriately	  and	  in	  accordance	  with	  guidelines	  but	  this	  does	  not	  appear	  to	  be	  the	  case,	  particularly	  with	  regard	  to	  platelets	  and	  FFP.	  
	  In	  this	  chapter	  the	  results	  of	  this	  study	  have	  been	  presented	  and	  discussed	  as	  per	  the	  research	  objectives.	  The	  data	  presented	  include	  demographic	  data	  of	  the	  study	  sample	  and	  responses	  to	  a	  questionnaire.	  The	  findings	  have	  been	  described	  and	  analysed	  using	  descriptive	  and	  inferential	  statistics.	  	  In	  the	  final	  chapter	  a	  summary,	  the	  limitations,	  recommendations	  and	  conclusions	  of	  the	  study	  are	  presented.	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Chapter	  5	  -­‐	  Summary,	  limitations,	  recommendations	  and	  
conclusions	  
	  In	  this	  chapter	  the	  purpose,	  objectives,	  study	  design	  and	  results	  of	  this	  study	  will	  be	  briefly	  reviewed.	  The	  limitations	  of	  the	  study	  will	  be	  addressed,	  recommendations	  for	  clinical	  practice	  and	  further	  research	  made	  and	  a	  conclusion	  presented.	  	  
5.1	  Summary	  of	  the	  study	  
	  
5.1.1	  Purpose	  of	  the	  study	  
	  The	  purpose	  of	  this	  study	  was	  to	  describe	  the	  level	  of	  clinicians’	  knowledge	  and	  awareness	  related	  to	  all	  aspects	  of	  the	  ordering	  and	  administration	  of	  blood	  products	  from	  the	  SANBS	  for	  perioperative	  patients	  at	  CHBAH.	  	  
5.1.2	  Objectives	  of	  the	  study	  
	  The	  primary	  objectives	  of	  this	  study	  were	  to	  determine	  the	  knowledge	  and	  awareness	  of	  clinicians	  with	  regard	  to:	  
• risks	  associated	  with	  the	  transfusion	  of	  blood	  products	  
• resources	  and	  costs	  associated	  with	  the	  transfusion	  of	  blood	  products	  
• donations,	  ordering	  and	  return	  of	  blood	  products	  
• safe	  administration	  of	  blood	  products	  to	  a	  patient	  
• transfusion	  thresholds	  and	  triggers	  for	  blood	  product	  administration.	  	  The	  secondary	  objectives	  of	  this	  study	  were	  to	  compare	  knowledge	  levels	  among	  the	  different	  specialty	  departments	  and	  clinician	  ranks.	  	  
5.1.3	  Summary	  of	  the	  research	  methodology	  used	  in	  the	  study	  
	  A	  prospective,	  descriptive,	  contextual	  study	  design	  was	  used.	  Clinicians	  working	  in	  the	  Anaesthesiology,	  General	  Surgery	  and	  Trauma,	  Orthopaedic	  Surgery	  and	  Obstetrics	  and	  Gynaecology	  Departments	  at	  CHBAH	  belonging	  to	  the	  professional	  levels	  intern,	  medical	  officer,	  registrar	  and	  consultant	  formed	  the	  sample	  group	  studied.	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A	  convenience	  sampling	  method,	  which	  involves	  the	  selection	  of	  readily	  available	  subjects	  or	  objects	  for	  a	  study	  (35),	  was	  used.	  Approximately	  600	  doctors	  are	  employed	  at	  CHBAH	  (32),	  of	  which	  about	  200	  work	  with	  perioperative	  patients	  (32).	  The	  true	  sample	  size	  was	  realised	  from	  the	  number	  of	  respondents	  (38).	  	  Clinicians	  were	  invited	  to	  take	  part	  in	  the	  study	  and	  were	  given	  a	  self-­‐administered	  questionnaire	  (Appendix	  4).	  The	  questionnaire	  contained	  an	  information	  letter	  (Appendix	  5)	  detailing	  the	  purpose	  of	  the	  study,	  Human	  Research	  Ethics	  Committee	  and	  CHBAH	  approvals.	  The	  agreement	  to	  complete	  the	  questionnaire	  implied	  consent.	  The	  questionnaires	  were	  distributed	  to	  those	  clinicians	  who	  agreed	  to	  participate	  in	  the	  study.	  The	  researcher	  collected	  questionnaires	  sealed	  in	  an	  unmarked	  envelope	  at	  the	  end	  of	  these	  meetings	  and	  placed	  them	  in	  a	  container	  for	  subsequent	  analysis.	  	  
5.1.4	  Summary	  of	  results	  
	  There	  were	  210	  questionnaires	  distributed	  with	  172	  (81.90%)	  returned.	  The	  departments	  of	  Anaesthesiology,	  General	  Surgery	  and	  Trauma,	  Orthopaedic	  Surgery,	  Obstetrics	  and	  Gynaecology	  were	  included.	  Interns,	  medical	  officers,	  registrars	  and	  consultants	  from	  these	  departments	  were	  included.	  	  The	  mean	  total	  (SD)	  for	  correctly	  answered	  questions	  was	  16.76	  (4.58)	  from	  32	  questions	  for	  all	  respondents.	  Anaesthesiolgy	  respondents	  mean	  was	  19.98	  (3.84),	  General	  Surgery	  and	  Trauma	  16.28	  (4.05),	  Orthopaedic	  Surgery	  13.83	  (4.17)	  and	  Obstetrics	  and	  Gynaecology	  15.63	  (3.51).	  	  Interns’	  mean	  was	  14.82	  (4.49),	  medical	  officers’	  15.65	  (4.03),	  registrars’	  17.0	  (4.34)	  and	  consultants’	  20.09	  (3.67).	  	  Clinicians’	  knowledge	  of	  the	  risks	  associated	  with	  blood	  product	  administration	  appears	  to	  be	  poor.	  Awareness	  of	  consent,	  costs,	  ordering	  and	  administration	  protocols	  was	  also	  disappointing.	  In	  this	  study	  respondents	  from	  Anaesthesiology	  performed	  significantly	  better	  than	  their	  colleagues	  and	  consultants	  performed	  significantly	  better	  than	  their	  junior	  colleagues.	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5.2	  Limitations	  of	  the	  study	  
	  The	  main	  limitations	  of	  this	  study	  lie	  in	  its	  design	  and	  sampling	  method.	  The	  study	  design	  was	  contextual	  in	  that	  it	  is	  limited	  to	  certain	  disciplines	  only	  and	  is	  confined	  to	  CHBAH.	  Results	  may	  not	  be	  applicable	  to	  other	  academic	  hospitals	  in	  South	  Africa.	  The	  study	  only	  provides	  insight	  to	  the	  situation	  at	  CHBAH.	  Also,	  interns	  and	  medical	  officers	  may	  only	  work	  in	  a	  particular	  department	  temporarily.	  	  The	  use	  of	  convenience	  sampling	  may	  contribute	  to	  bias.	  	  The	  questionnaires	  were	  distributed	  on	  chairs	  or	  desks	  prior	  to	  the	  meetings.	  The	  researcher	  attended	  the	  subsequent	  meeting	  to	  avoid	  data	  contamination.	  Blank	  questionnaires	  were	  recollected	  from	  the	  chairs	  or	  desks.	  It	  is	  not	  clear	  whether	  an	  individual	  chose	  not	  to	  complete	  the	  questionnaire	  or	  if	  no	  individual	  was	  seated	  there.	  	  As	  the	  study	  was	  reliant	  on	  a	  self-­‐administered	  questionnaire	  it	  depended	  on	  the	  honesty	  of	  respondents	  and	  the	  quality	  of	  their	  submitted	  data.	  The	  study	  also	  aimed	  to	  assess	  awareness	  of	  guidelines.	  However,	  awareness	  cannot	  be	  interpreted	  as	  use	  of,	  or	  adherence	  to	  these	  guidelines.	  Correct	  answers	  to	  the	  questionnaire	  may	  not	  have	  indicated	  awareness	  of	  the	  guidelines,	  but	  rather	  may	  reflect	  a	  consistency	  between	  the	  guidelines	  and	  the	  respondents’	  judgement	  and	  knowledge.	  The	  use	  of	  multiple	  choice	  questions	  in	  the	  questionnaire	  may	  have	  increased	  the	  measured	  levels	  of	  awareness	  by	  offering	  options	  that	  respondents	  may	  have	  been	  previously	  unaware.	  	  	  Heads	  of	  Departments	  and	  The	  Local	  Blood	  Committee	  were	  approached	  timeously	  for	  permission	  to	  conduct	  the	  study	  in	  their	  departments	  and	  were	  thus	  aware	  of	  the	  upcoming	  audit.	  This	  may	  have	  resulted	  in	  an	  effort	  to	  improve	  the	  education	  and	  knowledge	  of	  blood	  product	  administration	  and	  guidelines	  in	  anticipation	  of	  the	  study	  and	  hence,	  may	  not	  reflect	  reality.	  The	  results	  may	  have	  been	  influenced	  with	  exposure	  to	  guidelines	  or	  education	  that	  would	  occur	  with	  time	  or	  due	  to	  the	  need	  for	  awareness	  of	  guidelines	  that	  the	  study	  highlights.	  	  In	  practice,	  junior	  clinicians	  may	  be	  acting	  on	  the	  instruction	  of	  senior	  clinicians.	  This	  may	  have	  affected	  their	  responses.	  This	  study	  did	  not	  explore	  reasons	  for	  the	  apparent	  poor	  knowledge	  or	  whether	  guidelines	  are	  actually	  implemented.	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5.3	  Recommendations	  from	  the	  study	  
	  
5.3.1	  Recommendations	  for	  clinical	  practice	  
	  The	  study	  has	  addressed	  a	  relevant	  and	  particular	  knowledge	  deficit	  within	  the	  CHBAH	  and	  therefore	  is	  of	  value	  to	  the	  SANBS,	  management	  of	  the	  institution	  and	  clinical	  departments.	  Regular	  formal	  education	  on	  risk,	  resources,	  blood	  product	  ordering	  and	  administration	  with	  appropriate	  feedback	  may	  be	  of	  value.	  Regular	  audits	  and	  feedback	  are	  also	  recommended.	  Attaching	  information	  on	  costs,	  definitions	  and	  risks	  to	  the	  SANBS	  ordering	  form	  may	  be	  of	  benefit	  to	  clinicians	  and	  patients.	  The	  introduction	  of	  a	  MSBOS	  at	  CHBAH	  is	  also	  recommended.	  This	  will	  involve	  discussion	  with	  the	  SANBS,	  hospital	  management	  and	  medical	  colleagues.	  	  
	  
5.3.2	  Recommendations	  for	  further	  research	  
	  Research	  into	  reasons	  for	  the	  apparent	  poor	  knowledge	  and	  whether	  guidelines	  are	  actually	  implemented	  should	  be	  undertaken.	  Implementation	  and	  impact	  of	  any	  educational	  intervention	  must	  be	  followed	  up.	  The	  blood	  product	  transfusion	  seminar	  is	  a	  potential	  area	  for	  intervention.	  Should	  a	  MSBOS	  be	  introduced	  at	  CHBAH,	  the	  changes	  in	  ordering	  and	  administration	  patterns	  of	  blood	  products	  would	  need	  to	  be	  assessed.	  
	  
5.4	  Conclusion	  
	  Clinicians’	  knowledge	  of	  risks,	  resources,	  costs,	  ordering	  and	  return	  of	  blood	  products	  is	  discouraging.	  Disturbing	  trends	  appear	  to	  be	  common	  and	  in	  disagreement	  with	  some	  local	  and	  international	  guidelines.	  Of	  particular	  concern	  is	  the	  lack	  of	  appropriate	  knowledge	  to	  obtain	  informed	  consent	  and	  the	  lack	  of	  guidance	  with	  regard	  to	  FFP	  administration.	  	  It	  could	  be	  argued	  that	  knowledge	  of	  costs	  is	  inconsequential	  if	  blood	  products	  are	  used	  appropriately	  and	  in	  accordance	  with	  guidelines	  but	  this	  does	  not	  appear	  to	  be	  the	  case,	  particularly	  with	  regard	  to	  platelets	  and	  FFP.	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Appendix	  4:	  	  Questionnaire	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X;> A%082&9%$B01&7,"8="&3AAC4@ YENRR ENRRT!NRR E!NRRT>NRR E>NRRTFNRR EFNRRTKNRR UEKNRR '/.J,&3./2
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!R;> ]?*,(?(,6 %/?' +//-&:[ L/'0&:[ '/.\,&3./2
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5 10 20 50 100 150 don't+know
13 One+mega.unit'of'platelets+should+normally+raise+the+platelet+count+by+(x109/L)?
<10 10H20 20H60 >60 don't+know
14 What+would+you+regard+as+a+safe+platelet+count+(x109/L)+above+which+an+invasive'or'surgical'procedure+may+be+carried+out?
(not+ophthalmic+or+neurosurgical)
5 10 20 50 100 150 don't+know
15 Under+what+circumstances+do+you+administer+FFP?
15.1 coagulopathy+with+bleeding+due+to+clotting+factor+deficiency Yes No don't+know
15.2 abnormal+laboratory+clotting+studies+with+no+clinical+bleeding+(no+history+of+a+bleeding+diathesis) Yes No don't+know
15.3 abnormal+laboratory+clotting+studies+with+no+bleeding+prior+to+a+procedure+or+surgery Yes No don't+know
15.4 severe+burns Yes No don't+know
15.5 massive+transfusion Yes No don't+know
15.6 intravascular+volume+expansion Yes No don't+know
15.7 urgent+heparin+reversal Yes No don't+know
15.8 urgent+warfarin+reversal Yes No don't+know
16 What+is+the+correct+dose+of+FFP+in+adults?
1+unit 2+units 5ml/kg 10H20ml/kg 50ml/kg don't+know
17
5 6 7 8 9 10 +don't+know
18
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Appendix	  5:	  Information	  letter	  
	  Dear	  colleague,	  	  Hello,	  my	  name	  is	  Bradley	  Yudelowitz	  and	  I	  am	  an	  anaesthesiology	  registrar	  on	  the	  University	  of	  the	  Witwatersrand’s	  anaesthesiology	  registrar	  circuit.	  I	  would	  like	  to	  invite	  you	  to	  participate	  in	  a	  research	  study	  entitled:	  Knowledge	  and	  awareness	  of	  appropriate	  blood	  product	  use	  in	  perioperative	  patients	  among	  clinicians	  at	  an	  academic	  hospital.	  This	  will	  be	  handed	  in	  to	  the	  University	  of	  the	  Witwatersrand,	  Department	  of	  Health	  Sciences	  as	  part	  of	  my	  MMed	  degree.	  The	  study	  involves	  the	  assessment	  of	  blood	  product	  transfusion	  practices	  at	  Chris	  Hani	  Baragwanath	  Academic	  Hospital.	  	  	  The	  study	  has	  been	  approved	  by	  the	  Human	  Research	  Ethics	  Committee	  (HREC)	  (Medical)	  (Number	  M120748)	  and	  the	  Post-­‐graduate	  Committee	  of	  the	  University	  of	  the	  Witwatersrand.	  Furthermore,	  permission	  to	  conduct	  the	  study	  has	  been	  obtained	  from	  the	  CHBAH	  Medical	  Advisory	  Committee,	  Chairman	  of	  the	  Local	  Blood	  Committee	  and	  the	  heads	  of	  departments	  involved.	  	  	  Consent	  will	  be	  implied	  by	  agreeing	  to	  complete	  the	  questionnaire	  and	  is	  entirely	  voluntary.	  Please	  know	  that	  you	  are	  free	  to	  withdraw	  from	  the	  study	  at	  any	  time	  without	  having	  to	  provide	  a	  reason.	  Not	  taking	  part	  in	  or	  withdrawing	  from	  the	  study	  carries	  no	  penalty	  or	  repercussion	  of	  any	  sort.	  	  	  	  Questionnaires	  are	  not	  marked	  in	  any	  way	  for	  identification	  and	  no	  identifying	  data	  will	  be	  collected.	  The	  questionnaire	  should	  only	  take	  approximately	  10	  minutes	  to	  complete.	  Once	  completed	  questionnaires	  will	  be	  placed	  into	  a	  sealed	  envelope.	  The	  contents	  of	  the	  completed	  questionnaires	  will	  only	  be	  viewed	  by	  my	  research	  supervisors	  and	  myself.	  	  Results	  published	  will	  have	  no	  identifying	  data	  and	  will	  be	  made	  available	  to	  participants.	  	  The	  study	  offers	  no	  benefit	  to	  participants,	  but	  may	  result	  in	  positive	  changes	  for	  the	  future.	  	  If	  you	  have	  any	  questions	  or	  concerns	  with	  regard	  to	  the	  study,	  you	  may	  contact	  the	  following	  people	  with	  your	  queries:	  
• Professor	  Cleaton-­‐Jones	  (chairperson	  of	  the	  HREC):	  011	  717	  1234	  
• Bradley	  Yudelowitz	  (researcher):	  0827749114	  	  Thank	  you	  for	  taking	  the	  time	  to	  read	  this	  letter.	  	  	  Yours	  sincerely	  	  Bradley	  Yudelowitz	  	  	  	  	  	  	  	  
